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ABSTRACT 
In the last years, a new role for circulating bile acids has emerged, as they do not only aid in 
the absorption of dietary lipids but also may function as signaling molecules. Bile acids were 
identified to protect against diet-induced obesity (DIO) in C57BL/6J mice. It was hypothesized 
that this phenomenon is based on a bile acid-derived increase in thermogenic processes in 
brown adipose tissue, the adaptive heater organ in mammals. Yet, it has not been proven that 
the brown adipose tissue-specific Uncoupling Protein 1 (UCP1) which uncouples the 
respiratory chain and thereby dissipates energy as heat, is necessary within this context.  
We were able to verify the DIO-protective effect of bile acids in mice of the inbred mouse 
strain C57BL/6J. The mice were fully protected from fat mass accumulation, if their high-fat 
diet was supplemented with the primary bile acid cholic acid. Moreover, bile acid-
supplementation provoked browning and an increase in brown adipocyte markers in inguinal 
white adipose tissue. However, indirect calorimetry measurements revealed, that the 
adiposity-preventive effects could not be attributed to an increase in energy expenditure. 
To elucidate the contribution of a browning effect of bile acids, we used 129S6/SvEvTac mice, 
which naturally have a high propensity to recruit brite adipocytes. In contrast to expectations, 
129S6/SvEvTac mice were not at all influenced by cholic acid supplementation. All previously 
observed impacts on body mass, body composition, or brown adipocyte marker expression 
were absent in this strain, and no browning effect was detected. Differing bile acid 
concentrations in the organs of enterohepatic circulation reflected the strain specific response 
to bile acid supplementation. Eventually, variants of intestinal bile acid transporters may 
account for the observed variations and need to be further elucidated. 
To clarify the role of UCP1 in this regard, we compared the effect of cholic acid 
supplementation in C57BL/6J wildtype and Ucp1 knockout mice. No differences between both 
genotypes were detected in body mass development or body composition. Yet, we observed 
pathological increases in liver enzyme levels that hint at an impairment of liver functionality 
in both genotypes. 
Taking together, bile acid-derived prevention of diet-induced obesity in mice is strain specific 
and not dependent on Ucp1. 
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ZUSAMMENFASSUNG 
Gallensäuren erfüllen neben ihrer klassischen Rolle als Endprodukt des Cholesterin-
stoffwechsels und in der Fettverdauung auch eine Funktion als Signalmoleküle und schützen 
beispielsweise C57BL/6J Mäuse vor einer ernährungsbedingten Adipositas. Dafür 
verantwortlich gemacht wurde eine durch Gallensäuren verstärkte Thermogenese und damit 
ein erhöhter Energieverbrauch des Braunen Fettgewebes. Die Notwendigkeit des Braunfett-
Proteins Uncoupling Protein 1 (UCP1), welches die Atmungskette entkoppelt und dadurch 
Energie als Wärme freisetzt, wurde bisher jedoch nicht zweifelsfrei bewiesen. 
In unserer Studie konnte die protektive Wirkung der primären Gallensäure Cholsäure in 
Mäusen des Inzuchtstammes C57BL/6J nachgewiesen werden. Die Entstehung einer 
Adipositas durch eine fettreiche Diät konnte in den Tieren, welche zusätzlich mit Cholat 
supplementiert wurden, verhindert werden. Darüber hinaus bewirkte die 
Cholatsupplementation eine erhöhte Expression verschiedener Braunfett-Marker-Gene sowie 
das Browning des inguinalen weißen Fettgewebes. Mithilfe der indirekten Kalorimetrie konnte 
jedoch nachgewiesen werden, dass die gallensäurebedingte Adipositasprävention nicht auf 
eine Erhöhung des Energieverbrauchs zurückzuführen ist. 
Um den Browning-Effekt der Gallensäuren zu verstärken, sollten die Ergebnisse in Mäusen des 
Inzuchtstamms 129S6/SvEvTac verifiziert werden, da Tiere dieses Stamms eine natürlich hohe 
Neigung besitzen, Brite-Adipozyten zu rekrutieren. Entgegen der Erwartungen zeigte die 
Cholatsupplementation keinerlei Einfluss auf diese Tiere. Weder der Adipositas-präventive 
Effekt des Cholats, noch dessen Browning-Kapazität konnte in 129S6/SvEvTac Mäusen 
nachgewiesen werden. Hinweise auf mögliche Stammunterschiede lieferte dabei die 
Gallensäure-Analytik, welche unterschiedliche Gallensäurekonzentrationen in den Organen 
des enterohepatischen Kreislaufs zu Tage brachte. Verschiedene Gallensäuretransporter-
Varianten im Darm könnten hierbei die beobachteten Veränderungen erklären. 
Um die Rolle von UCP1 in diesem Zusammenhang zweifelsfrei klären zu können, wurde die 
Wirkung der Cholatsupplementation in C57BL/6J-Wildtyp- und Ucp1-Knockout-Mäusen 
verglichen. Es wurden dabei keine Unterschiede zwischen den Genotypen identifiziert. Wir 
beobachteten jedoch einen pathologischen Anstieg der Leberenzymspiegel, der auf eine 
Beeinträchtigung der Leberfunktion in beiden Genotypen hindeutet. 
Zusammenfassend wurde damit erstmals gezeigt, dass die Gallensäure-bedingte Prävention 
Diät-induzierter Adipositas in Mäusen stammspezifisch sowie Ucp1-unabhängig ist. 
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1    INTRODUCTION 
1.1   Bile acid synthesis, chemistry and function 
Bile acids (BAs) are a group of water-soluble steroids that are synthesized in hepatocytes 
during cholesterol catabolism. They are endogenous detergents (Berry and Reichen, 1983) 
and thereby help in digestion and absorption of fats. They emulsify dietary lipids and the 
products of digestion including cholesterol, phospholipids and fatty acids (Jenkins and Hardie, 
2008).  
Bile is formed by the net movement of water and solutes into the bile canaliculi (Reuben, 
1984). Bile secretion is sensitive to metabolic inhibitors (Hofmann, 1990) and temperature 
changes, as bile flow increases with increasing temperature (Brauer et al., 1954), but it is 
independent of hepatic perfusion within physiological ranges (Tavoloni et al., 1978). Healthy 
human subjects normally possess an endogenous bile acid pool of 1.25 to 4 g and daily 
synthesize approximately 250 to 500 mg under steady-state conditions to compensate for the 
fecal loss. The whole BA pool daily cycles five to 15 times through the enterohepatic circulation 
(Berry and Reichen, 1983).  
The human liver synthesizes the primary BAs cholic acid (CA) and chenodeoxycholic acid 
(CDCA) from cholesterol via different intermediates, with cholesterol 7 alpha-hydroxylase 
(CYP7A1) being the rate limiting enzyme. Prior to excretion, BAs are conjugated at the carboxyl 
group with glycine and taurine, normally in a ratio of 3 to 1. Glycine-conjugated BAs are the 
most abundant conjugated BAs, representing more than 70 % of bile, taurine-conjugated BAs 
represent more tha 20 % of bile (Jenkins and Hardie, 2008). Sulfation and glucuronidation can 
occur at the hydroxyl groups (Berry and Reichen, 1983). These detoxifying mechanisms can be 
intensified under pathologic conditions as e.g. intrahepatic cholestasis, where hepatic BA 
levels reach toxic concentrations (Makino et al., 1975; Stiehl et al., 1980). Bile salts form mixed 
micelles with phospholipids and cholesterol and are stored in the gallbladder (Chiang, 2013). 
After secretion into the intestine, secondary bile acids are formed by bacterial 
dehydroxylation, with deoxycholic acid (DCA) and lithocholic acid (LCA) being the main 
secondary bile acids. Tertiary bile acids are formed in the liver by epimerization of secondary 
BAs, which were recycled via enterohepatic circulation (term definition: see 1.2). In humans, 
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ursodeoxycholic acid (UDCA) is the main tertiary bile acid and is e.g. found in relatively large 
amounts in sera of hyperlipidemic patients (Pennington et al., 1978), as it possesses a lower 
toxicity compared to e.g. CDCA and DCA (Leuschner et al., 1989), and is nowadays used as a 
drug for the treatment of various liver diseases (Eggert et al., 2014). Different BAs possess 
different absorption efficiencies, therefore the daily synthesis and fractional turnover rates 
vary for individual BAs (Angelin et al., 1982).  
In mice, the primary BAs cholic acid, alpha-muricholic acid (MCA)  and beta-muricholic acid 
(MCA), as well as small amounts of chenodeoxycholic (CDCA) and allocholic acid are present, 
as studies in germ-free mice revealed. In conventional mice, the secondary BAS lithocholic 
(LCA), deoxycholic ACID (DCA) and omega-muricholic acid (MCA) were identified (Eyssen et 
al., 1976). 
1.2   Physiologic bile acid regulation 
Bile secretion has a pivotal role in the excretion of both endogenous and exogenous 
compounds. Many waste products, including bilirubin, are removed from the body by 
secretion into bile and elimination with feces (Hofmann, 1988). Due to their amphipathic 
properties, BAs can emulsify lipid compounds, e.g. for fat absorption. Their ability to solubilize 
fats into emulsions is also potentially toxic for cells depending on lipid membranes maintaining 
their integrity. Consequently, the process from BA synthesis through the enterohepatic 
circulation to excretion must be tightly regulated using complex arrangements of chemical 
pumps (Jenkins and Hardie, 2008). In plasma, BAs circulate mainly bound to albumin, 
minimizing free concentrations of BAs (Kramer et al., 1979). Protein-bound BAs in plasma are 
removed with high efficiency by the hepatocytes, with over 80 % extraction of BAs in one pass 
(Paumgartner and Reichen, 1976). Retuning in portal blood, they are taken up by the 
hepatocyte via the sodium taurocholate co-transporting polypeptide (NTCP) and organic-
anion-transporting polypeptide (OATP) (Hagenbuch and Meier, 1996) (Fig. 1). The transport 
of BAs from hepatocyte into bile via the canaliculi is rate-limited by the activity of the bile-salt 
export pump (BSEP), playing a crucial role both in control of intra-cellular concentrations of 
BAs in the hepatocyte and in secretion of bile. Dietary supplementation of CA to mice leads to 
an up-regulation of BSEP gene expression by the nuclear BA receptor farnesoid X receptor 
(FXR), which also demonstrates the role of this receptor as a sensor for the intra-cellular BA 
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concentration (Sinal et al., 2000). Other transporters that export BAs from the hepatocyte e.g. 
are the multidrug resistance-related proteins MRP2 and MRP3, two ABC-transporters, that 
have a merely wide range of substrates and export BAs from hepatocytes into canaliculus 
(MRP2) or blood (MRP3), respectively, on a limited scale (Gerk and Vore, 2002; Teng and 
Piquette-Miller, 2007) (Fig. 2). 
BA secretion into bile canaliculi stimulates secretion of phospholipids and probably 
cholesterol, protecting canalicular membrane against the toxic effects of BAs (Coleman et al., 
1979). Cholangiocytes, which are the epithelial cells lining the bile ducts, possess amongst 
others the apical sodium-dependent BA transporter (ASBT). With ASBT, BAs can be absorbed 
from the bile-duct lumen to cycle back to hepatocytes. This uptake mechanism activates a 
process called “cholehepatic shunting”, which increases biliary lipid and fluid secretion by the 
 
Fig. 1: Hepatocyte basolateral BA 
transporters. Protein-bound BAs returning 
in portal blood are taken up by the 
hepatocyte via the sodium taurocholate co-
transporting poly-peptide (NTCP) and 
organic-anion-transporting polypeptide 
(OATP). In cholestasis BAs may be returned 
to blood by the multi-drug-resistance-
associated protein 3 (MRP3). BAs cross the 
hepatocyte bound to 3a-hydroxysteroid 
dehydrogenase (adapted from Jenkins et 
al., 2008). 
 
 
Fig. 2: Secretion of BAs and biliary 
components. BAs are exported into the 
canaliculus by the bile-salt export protein 
(BSEP). Phosphatidylcholine (PC) from the 
inner leaflet of the apical membrane is 
flipped to the outer layer and interacts with 
BAs secreted by BSEP. BAs, PC, together 
with cholesterol from the membrane form 
mixed micelles that are not toxic to 
epithelial membranes of the biliary tree. 
Aquaporins (AQP) secrete water into bile 
(adapted from Jenkins et al., 2008). 
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hepatocyte, thus eliminating toxic bile with high efficiency, especially during increased BA 
levels (Alpini et al., 2005; Lamri et al., 1992), e.g. occurring during cholestasis (Woolbright et 
al., 2015) or after dietary BA administration (Watanabe et al., 2006) (Fig. 3). 
After its synthesis in hepatocytes and excretion to the ducts, bile can be stored in the 
gallbladder, a storage and concentrating system for bile during inter-digestive phases (Fahey 
et al., 1995). Subsequent to food intake, the gallbladder contracts and ejects a bolus of bile 
into the small bowel where they facilitate fat digestion. Water-soluble pancreatic lipase acts 
at the surface of intestinal lipid droplets to hydrolyze dietary triglycerides. BAs aid this process 
by their detergent properties that cause the formation of smaller lipid droplets and thereby 
increase surface area available for the lipase. The detergent molecules form micelles, which 
solubilize monoglycerides and fatty acid. Partially, intestinal BA absorption occurs passively, 
e.g. for unconjugated BAs that have pK values of around 6 and therefore are un-ionized in the 
intestinal lumen. However, the majority of BAs are conjugated and ionized and therefore 
require transporters to cross the enterocyte. The majority of BAs is transported Na+-
dependently by ASBT from the small bowel lumen into enterocytes. ASBT mainly transports 
conjugates, but can also transport unconjugated BAs (Jenkins and Hardie, 2008). In 
comparison to ileal absorption, the mechanisms responsible for transport of BAs in the 
proximal intestine and their quantitative significance are not as well defined (Dawson et al., 
2009). As BAs enter the enterocyte, they are mostly bound to intestinal BA-binding protein 
(IBABP) to be transported intracellular across the enterocyte (Vodenlich et al., 1991). BA 
export from enterocytes into portal blood is majorly driven by the heteromeric organic-solute 
transporter (OST). OSTα and OSTβ actively transport BAs and some steroids (Seward et al., 
2003).  
Comparably high levels of OSTα/OSTβ are found at the basolateral membrane of ileal 
enterocytes and function via a facilitated diffusion mechanism (Ballatori et al., 2013). Other 
transporters that also are present at the basolateral side may have a role in BA efflux from the 
enterocyte, too, but this remains to be further defined (Jenkins and Hardie, 2008) (Fig. 4). 
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Beyond enterohepatic circulation, BAs can also escape hepatic extraction and spillover into 
systemic circulation. As BAs are bound to plasma proteins, glomerular filtration and urinary 
excretion is reduced. Yet, a small fraction of BAs is also excreted in the urine. Due to a highly 
efficient tubular reabsorption (Weiner et al., 1964; Wilson et al., 1981), only 1-2 µmol of BAs 
are found in the urine of healthy patients despite an originally filtered amount of approx. 
100 µmol per day (Stiehl, 1974). However, this process contributes to the rise in serum BA 
concentrations in patients with cholestatic liver disease (Dawson et al., 2009). Even in case of 
 
Fig. 3: BA absorption by the cholangiocyte in the 
cholehepatic shunt. BAs are absorbed at the 
apical membrane of the cholangiocyte by the 
apical sodium-dependent BA transporter (ASBT) 
that causes cholehepatic shunting of BAs back to 
the hepatocyte. Absorbed BAs are exported 
across the basolateral membrane by multi-drug-
resistance-associated protein 3 (MRP3), a 
truncated form of ASBT or by OSTα/OSTβ. BAs 
cause choleresis that is rich in bicarbonate ions 
secreted by the chloride/bicarbonate ion 
exchanger (adapted from Jenkins et al., 2008). 
 
 
Fig. 4: BA absorption from the small bowel 
lumen. BAs are efficiently transported from 
the lumen of the terminal ileum by the apical 
sodium-dependent BA transporter (ASBT). 
Unconjugated BAs will be un-ionised at the 
pH of the lumen and may be passively 
absorbed. Within the enterocyte BAs are 
bound by the intestinal BA-binding protein 
(IBABP). Efflux from the enterocyte may 
involve the truncated ASBT (tASBT) and/or 
multi-drug-resistance-associated protein 3 
(MRP3) but this remains to be defined. 
OSTα/OSTβ gene products together but not 
separately transport BAs out of the 
enterocyte. OATP3 mRNA has been identified 
but it is not yet clear whether the protein is 
functional (adapted from Jenkins et al., 
2008). 
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elevated plasma BA concentrations, e.g. in patients with cholestatic liver disease, the 24-h 
urinary excretion of nonsulfated BAs is significantly less than the quantity that undergoes 
glomerular filtration (Raedsch et al., 1981; Rudman and Kendall, 1957; Stiehl et al., 1975). 
1.3   Bile acids and metabolic regulation 
In the last years, a new role for BAs as signaling molecules has emerged. BAs do not only aid 
in the absorption of dietary lipids, but also function as metabolic regulators. For example, BAs 
activate mitogen-activated protein kinase (MAPK) signaling pathways (Gupta et al., 2001; Qiao 
et al., 2003) and are natural ligands for the nuclear hormone receptor farnesoid X receptor 
(FXR) (Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999) as well as G-protein-
coupled receptors (GPCRs) such as TGR5 (Kawamata et al., 2003; Maruyama et al., 2002).  
FXR is a transcription factor that controls both the biosynthesis and enterohepatic recycling 
of BAs and regulates the expression of the short heterodimer partner (SHP). SHP inhibits the 
activity of other nuclear receptors like the liver X receptors LXRα and LXRβ, both necessary for 
the transcriptional induction of CYP7A1, the rate-limiting enzyme of BA biosynthesis. Thereby, 
the FXR-mediated SHP-induction contributes to the negative feedback regulation of BA 
biosynthesis (Brendel et al., 2002; Goodwin et al., 2000; Lu et al., 2000). Moreover, FXR 
induces the fibroblast growth factor FGF19 (FGF15 in mice) in intestinal epithelial cells, which 
passes to the liver and acts on the FGFR4 (Inagaki et al., 2005; Stroeve et al., 2010) (Fig. 5). 
Thereby, the hepatic FXR-mediated SHP induction after BA administration inhibits fatty acid 
and triglyceride biosynthesis and VLDL production (Watanabe et al., 2004). In this way, BAs 
control their own levels as well as those of their precursor, cholesterol. 
TGR5, as a member of GPCRs, was discovered in 2002 (Maruyama et al., 2002). High levels of 
TGR5 mRNA can be detected in several organs such as small intestine, stomach, liver, lung, 
placenta and spleen (Keitel et al., 2007; Tiwari and Maiti, 2009). Bile acids are the endogenous 
natural agonists of TGR5 (Guo et al., 2016). They activate TGR5 and thereby induce cAMP 
production (Maruyama et al., 2002). TGR5 activation also causes increased intracellular cAMP 
levels in brown adipose tissue (BAT) and skeletal muscle. This leads to an activation of type 2 
iodothyronine deiodinase (D2), which converts inactive thyroxine (T4) to active 3,5,3’-
triiodothyronine (T3) (Bianco et al., 2002). The following saturation of thyroid hormone 
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receptor as well as the activation of PGC-1α leads to an induction of energy expenditure in 
BAT and skeletal muscle (Watanabe et al., 2006). Moreover, TGR5 signaling induces intestinal 
glucagon-like peptide-1 (GLP-1) release in entero-endocrine L-cells and thereby increases 
insulin secretion (Thomas et al., 2009) (Fig. 5). Taken together, BAs not only help in lipid 
digestion, but were also shown to be potent metabolic regulators. The underlying mechanisms 
have to be further elucidated, yet. 
 
Fig. 5: Impact on energy metabolism after FXR activation, e.g. by BAs or GW4064. Administration of 
the synthetic FXR agonist GW4064 to high-fat diet fed mice leads to a reduction in BA synthesis and 
reduced BA pool size. This translates into reduced energy expenditure in BAT, TG accumulation in WAT, 
BAT, and liver, as well as insulin resistance. As BAs are natural ligands for FXR and activate equal signal 
transduction routes, similar effects can be observed (adapted from Watanabe et al., 2011). 
1.4   Brown, white and brite- the different types of adipose tissue 
To date we are aware of three different adipose tissue types: brown, white and brite adipose 
tissue.  
White adipose tissue (WAT) principally is an energy storage that stores dietary energy in times 
of excess energy intake and releases fatty acids when fuel is required. In the last decades, 
however, WAT was also discovered to inherit a complex metabolic role. It is an endocrine 
organ that produces a myriad of endocrine factors called adipokines (Villarroya et al., 2013). 
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The tissue is e.g. needed for normal glucose homeostasis and plays a role in inflammatory 
processes through preadipocytes acting as macrophage-like cells (Cousin et al., 1999). A 
radical change in perspective followed the discovery of leptin, as this critical hormone in 
energy balance is produced principally by white fat, giving the tissue an endocrine function. 
Indeed, there is a growing list of protein signals and factors that are released from white 
adipocytes (Ailhaud, 2000; Mohamed-Ali et al., 1998). These proteins released by WAT are 
e.g. inflammatory cytokines, play a role in lipid metabolism, and are involved in vascular 
haemostasis or the complement system. In essence, WAT is a major secretory and endocrine 
organ, that plays a wide-ranging role in metabolic regulation and physiological homeostasis, 
far beyond the simple paradigm of fat storage (Trayhurn and Beattie, 2001). 
In contrast to WAT, the brown adipose tissue (BAT) is not primarily responsible for lipid 
storage, but rather is the main site of non-shivering thermogenesis in mammals. BAT is found 
in almost all mammals and is mainly located at the interscapular region. The active brown fat 
cell has a round centrally placed nucleus and a granular cytoplasm containing multiple fat 
vacuoles. It is thus often referred to as multilocular, in contrast to white fat, which is unilocular 
(Heaton, 1972). The thermogenic processes in BAT are driven by its large number of 
mitochondria, which also confer the brownish appearance to BAT. They possess a unique 
biochemical property, wherein the brown adipocyte-specific protein, the mitochondrial 
carrier protein uncoupling protein 1 (UCP1), uncouples the respiratory chain and thereby 
dissipates chemical energy as heat. These effects are physiologically activated e.g. in response 
to cold (Klingenspor et al., 2008). Furthermore, BAT is also known to be a possible site of diet-
induced thermogenesis. In response to cold as well as to overfeeding, an activation of the 
sympathetic nervous system is triggered. Thereby, the thermogenic activity of BAT is induced 
via distinct cellular processes, including the rapid activation of the existing UCP1 as well as 
transcriptional induction of the genes encoding UCP1. Moreover, enzymes responsible for 
oxidizing metabolic substrates, and components of the cellular machinery responsible for the 
active uptake of lipids and glucose from the circulation, are induced to sustain oxidation and 
thermogenesis (Cannon and Nedergaard, 2004; Giralt and Villarroya, 2013). In man, brown fat 
was once considered only necessary in newborns. However, recent morphological and 
imaging studies have provided evidence that, contrary to prior belief, this tissue is present and 
active in adult humans (Nedergaard et al., 2007; Townsend and Tseng, 2012). It is speculated, 
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that the functional BAT has a distinct influence on the prevention of obesity. Ablation of BAT 
has been shown to sensitize organisms to obesity in several experimental settings (Hamann 
et al., 1998; Lowell et al., 1993). In contrast, the genetic knockout of the UCP1-encoding gene 
provided partly conflicting data on the development of obesity under different experimental 
settings. On the one hand, Ucp1 ko mice were described to be DIO-resistant at room 
temperature (20° C), as they have to maintain normal body temperature without non-
shivering thermogenesis, but by using less efficient, more energy consumptive pathways of 
metabolism (Liu et al., 2003). Some investigations failed to demonstrate an obese phenotype 
in Ucp1-ablated mice and did not observe differences in resting oxygen consumption between 
Ucp1-ko and wildtype mice at 28°C (Enerback et al., 1997). In contrast, another study showed 
that an Ucp1-ablation in itself is sufficient to induce obesity under thermoneutral conditions 
(Feldmann et al., 2009). For this reason, scientific examinations that investigate anti-
obesogenic properties on Ucp1-ablated mice need to be performed with an adequate control 
group that investigates whether the ko-mice can develop obesity under the specific present 
conditions. 
Besides its capacity of metabolite oxidation for thermogenesis, accumulating evidence 
indicates that BAT also exhibits an endocrine role, as genetically mediated ablation of BAT 
(Hamann et al., 1996; Lowell et al., 1993) had a much more profound impact on metabolism 
than specific blockage of BAT thermogenic activity via Ucp1 invalidation (Enerback et al., 
1997). It is assumed, that the endocrine factors possibly released by BAT, and termed 
“batokines” (for “BAT adipokines”) (Stanford et al., 2013; Townsend and Tseng, 2012), may 
have different or probably opposite effects than those of the WAT adipokines, act on other 
tissues, and will be actively released if BAT is activated. The endocrine function of BAT is not 
doubtlessly proved, so far. However, BAT is deemed to release autocrine or paracrine factors, 
amongst others T3, angiotensinogen, or also FGF21, which is induced upon cold and 
adrenergic stimulation (Townsend and Tseng, 2012; Villarroya et al., 2013). 
In humans, there were also found BAT-like depots, e.g. in the supraclavicular, but also in the 
interscapular regions of the body. Initially, it was believed to be the equivalent of the 
interscapular thermogenic organ of small mammals. However, this view was disputed, as it 
was demonstrated, that this depot consists of a newly identified type of brown adipocytes 
that is distinct from the classical brown adipocytes (Lidell et al., 2013): 
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In addition the “classical” two adipose tissues WAT and BAT, cells exhibiting a brown adipocyte 
thermogenic phenotype, but appear in WAT depots after thermogenic activation have been 
identified and characterized. These so-called “brite” (from “brown in white”) or also “beige” 
adipocytes are multilocular and express Ucp1. Classical brown adipocytes present in BAT 
depots are closely related to skeletal muscle precursors (Seale et al., 2008; Timmons et al., 
2007) and in fact, both brown adipocytes and myocytes share a common precursor that 
expresses the myogenic lineage marker Myf5. In contrast, brite adipocytes were found to 
come from Myf5-negative cells that more closely resemble white adipocyte precursors (Seale 
et al., 2008). Different processes that give rise to brite adipocytes are discussed: On the one 
hand, the browning process seems to arise partly or in whole via the transdifferentiation of 
white adipocytes into brite adipocytes (Barbatelli et al., 2010). Besides, genetic labelling of 
adipose cells supports the existence of bidirectional interconversion processes between brite 
and white adipocytes (Rosenwald et al., 2013). Indeed, brite adipocytes apparently represent 
intermediate forms of adipocytes, as they do not only express Ucp1 and reside in WAT depots, 
but also are mitochondria-rich, multilocular and show a lipid droplet distribution intermediate 
between that of brown and white adipocytes. According to some, these “paucilocular” 
adipocytes may constitute transition states from white to brite adipocytes (Barbatelli et al., 
1993; Himms-Hagen et al., 2000). On the other hand, some reports indicated that β3-
adrenergic activation induces browning through two different processes: white to brown 
transdifferentiation in inguinal WAT, but proliferation and further differentiation of 
precursors in epididymial WAT (Giralt and Villarroya, 2013; Lee et al., 2012). Moreover, the 
hitherto distinct separation into adipocytes with Myf5-positive or Myf5-negative precursor 
cells has been challenged to some extent by the finding that Myf5-positive precursors may 
also differentiate to white adipocytes (Sanchez-Gurmaches et al., 2012; Schulz et al., 2013).  
Despite the unclear origination of brite cells, there is genetic evidence that the capacity to 
induce these cells is highly relevant for protection against obesity in rodents (Guerra et al., 
1998). Inversely, mouse strains that have an increased tendency to become obese rather show 
decreased capacities for browning of WAT depots compared with those of obesity-resistant 
strains, despite similar BAT size, activity and capacity to recruit classical BAT in response to 
thermogenic activation (Guerra et al., 1998; Xue et al., 2007). These results suggest that the 
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browning process has a special, independent relevance in protection against obesity (Giralt 
and Villarroya, 2013). 
1.5   Effect of bile acids on obesity 
Obesity is a global epidemic that causes significant morbidity and mortality (Jenkins and 
Hardie, 2008). Manifold approaches from public education, to legislative procedures, to 
medical treatments are studied and applied to encounter this complex of problems. Thereby 
always new paths are struck. In the last years, a new role for bile acids as signaling molecules 
and metabolic regulators has emerged. Traditionally, BAs have been linked to the 
development of obesity through their role in the intestinal absorption of fatty acids. However, 
recent studies indicate that BAs have a much wider role in the regulation of energy balance in 
the body (Jenkins and Hardie, 2008). 
In 1997, a study by Ikemoto and colleagues was the first to suggest a link for BAs in the 
regulation of obesity. They demonstrated that the addition of the common bile salt sodium 
cholate (0.5 %) to a high-fat diet prevented increases in total body weight and WAT in 
C57BL/6J mice compared to littermates fed a non-supplemented high-fat diet. These effects 
occurred despite similar energy intakes across control (high-carbohydrate), high-fat and 
cholate-supplemented high-fat diet groups, indicating that the cholate-associated effect was 
not simply a reflection of reduced calorie intake in the supplemented animals. Cholate 
supplementation also prevented the development of hyperglycemia and reduced blood 
insulin levels compared with high-fat-diet-fed animals. Similar effects were reported with 
supplementation of the other primary BA, CDCA (Ikemoto et al., 1997). 
Watanabe and colleagues confirmed and extended these findings, as they directly linked BAs 
to the regulation of thermogenesis. It was demonstrated that CA-supplementation does not 
only reduce high-fat-diet-induced weight gain but also reverses the established weight gain in 
obese mice, resulting in reduced WAT mass and improved glucose tolerance. These effects 
were described to result from increased energy expenditure in CA-supplemented animals, 
rather than reduced caloric intake, as these animals showed a higher O2 consumption and CO2 
production compared to control animals during short-term indirect calorimetry 
measurements (Watanabe et al., 2006) (Fig. 6).  
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Fig. 6: Schematic illustration of bile acid-derived induction of thermogenesis. During digestion, bile 
acids are secreted with bile from the gallbladder and released into the intestine to emulsify dietary 
lipids, etc. They can be transferred back to the hepatocytes by intestinal reabsorption. Besides this 
recycling mechanism, which is called “enterohepatic circulation”, BAs also spillover from liver into 
systemic blood circulation. Thereby they reach peripheral sites of action, amongst others brown 
adipose tissue, where they are supposed to bind to the G-protein-coupled BA receptor TGR5, thereby 
increase Ucp1 expression and induce thermogenesis. 
Moreover, electron microscopy revealed that CA-supplementation resulted in an increased 
number of BAT mitochondrial lamellar cristae. Microarray analysis showed a strong up-
regulation of type-2 iodothyronine deiodinase (D2) mRNA in BAT of CA supplemented animals 
(Watanabe et al., 2006). The enzyme D2 converts thyroxine (T4) to active 3,5,3-tri-
iodothyronine (T3) and is required for adaptive thermogenesis in BAT (Bianco et al., 2002). 
The authors suggested that this effect was mediated via the G-protein-coupled BA receptor 
(GPBAR-1 or TGR5) resulting in a BA-derived cAMP-PKA activation in BAT cells (Fig. 7). TGR5 is 
ubiquitously expressed in humans and animals (Duboc et al., 2014) and its signal transduction 
is stimulated in varying intense, dependent on the respective BA. For example in HEK293-
hBG37 cells, the rank order of potency was LCA > DCA > CDCA > CA (Maruyama et al., 2002). 
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Fig. 7: The effect of BAs on energy expenditure. Circulating BAs bind to the G-protein-coupled BA 
receptor TGR5, which stimulates increased cAMP-PKA activation and increased expression of D2. This 
response is sensitized by a high-fat diet. D2 converts T4 to active T3, which stimulates thyroid hormone 
receptor binding to target genes. This leads to an altered expression of genes associated with energy 
balance and increased energy expenditure (adapted from Jenkins and Hardie, 2008). 
Besides TGR5, BAs are also natural ligands for the farnesoid X receptor (FXR). FXR belongs to 
the nuclear hormone receptor family and is activated most potently by the hydrophobic BA 
CDCA, whereas hydrophilic UDCA demonstrates little activity (Makishima et al., 1999; Parks et 
al., 1999; Wang et al., 1999). FXR activation leads to a decreased endogenous BA production, 
and thereby protects liver cells against toxic high BA levels. Moreover FXR directly affects 
adipocyte differentiation and function and may play an important role in the regulation of 
systemic lipid metabolism and peripheral glucose homeostasis (Kalaany and Mangelsdorf, 
2006). The loss of FXR using a gene knockout model results in impaired adipocyte 
differentiation, impaired glucose tolerance, insulin resistance and dyslipidemia (Cariou et al., 
2007; Rizzo et al., 2006; Sinal et al., 2000). These data raise the possibility that targeted FXR 
activation may also be useful to manage various aspects of the metabolic phenotype including 
type-2 diabetes, dyslipidemia and adipocyte function (Jenkins and Hardie, 2008). 
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In summary, the findings of the recent years raised the possibility that targeting BA signaling 
pathways may ameliorate obesity and associated pathologies such as insulin resistance, 
impaired glucose tolerance and dyslipidemia and promise to be highly active areas of research 
in the future (Jenkins and Hardie, 2008). However, BAs are potent detergents that may disrupt 
cell membranes and can promote the generation of reactive oxygen species that, in turn, 
oxidatively modify lipids, proteins, and nucleic acids, and eventually cause hepatocyte necrosis 
and apoptosis. Toxic BAs, especially hydrophobic BAs, can activate hepatocyte death 
receptors directly and induce oxidative damage. Thereby mitochondrial dysfunction is caused, 
and endoplasmic reticulum stress is induced (Perez and Briz, 2009). For this reason, the direct 
impacts of a BA-supplementation always have to be calculated and its risks need to be 
balanced against its potential advantages. 
1.6   Aims and scope 
This study is based on the studies of Watanabe and colleagues from 2006, showing that a 
dietary BA-supplementation prevents and ameliorates diet-induced obesity in mice fed a high-
fat diet by a mechanism dependent on type-2 deiodinase (Watanabe et al., 2006). However, 
the authors did not provide a substantive, direct proof of neither brown adipose tissue 
recruitment nor UCP1 activation within this context. In order to prove the reproducibility of 
their experiment, Watanabe’s key experiment should initially be repeated. Afterwards, the 
Ucp1 ko mouse model was used to directly prove the role of UCP1 in BA-derived protection of 
obesity. Additionally, 129S6/SvEvTac mice were used to assess the potential anti-obesogenic 
effects of white adipose tissue browning within this context. With the help of the obtained 
findings, we would be able to further enlighten and investigate the underlying molecular 
mechanisms of BA-mediated DIO-prevention.
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2    MATERIAL AND METHODS 
2.1   Animals  
We employed male mice of the C57BL/6J and 129S6/SvEvTac inbred strains bred in our 
specified pathogen-free facility (at TU München, Kleintierforschungszentrum, Freising, 
Germany) with regular hygiene monitoring according to FELASA (Federation of European 
Laboratory Animal Science Associations)  criteria at 50-60 % relative humidity, 22 °C ± 1°C and 
a 12-hour light/dark cycle. All mice received standard rodent chow diet (V1124-300, Ssniff 
Spezialdiäten GmbH) prior to experiments. They were housed in individually ventilated cages 
(IVC, type II long, 540 cm², Tecniplast, USA) up to five animals per cage. 
Uncoupling protein 1 (Ucp1) knockout (ko) mice on C57BL/6J background were generated by 
Leslie Kozak and coworkers (Enerback et al., 1997; Hofmann et al., 2001) and founder mice 
were kindly provided to establish our colony. Wildtype (wt) and Ucp1 ko mice obtained from 
heterozygous breeding were mated in homozygous wt/wt and ko/ko breeding pairs. These 
pairs were kept at 30 °C inside a climate cabinet (HPP749, Memmert), where offspring was 
born, raised and subjected to experiments. Homozygous breeding allowed a usage of 
averagely 50 % of the offspring (only male mice). This approach facilitated direct comparisons 
of littermates, as usually more than one male offspring was born in each litter (in contrast to 
this approach, breeding heterozygous mice results in only one male, homozygous mouse 
(Ucp1+/+ or Ucp1-/-) each litter on average). Up to five animals were kept in open cages (type 
II long, 540 cm², Tecniplast, USA) with a 12-hour light/dark cycle and relative humidity of 50-
60 %. Procedures were carried out in accordance with the German animal welfare law and 
approved by the Regional Government of Oberbayern, Germany. 
2.2   Diets 
Data were collected in three independent experiments characterized by the administration of 
four diets. Mice received control (C, S5745-E702) or high-fat (H, S5745-E712) diet providing 
13 % or 48 % of energy from fat, respectively. To investigate the effect of dietary BA 
administration, these diets were supplemented with 0.5 % (w/w) sodium cholate at the 
expense of cornstarch to generate C + cholate (CC, S5745-706) and H + cholate (HC, S5745-
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716) diets. All diets were obtained from Ssniff Spezialdiäten GmbH, Germany and fed ad 
libitum: 
1) C: low fat control diet (5 % soy oil, 5 % saccharose; ssniff order number S5745-E702) 
2) CC: low fat control diet containing 0.5 % cholic acid (ssniff order number S5745-E706) 
3) H: high-fat diet (20 % palm oil, 5 % soy oil, 5 % saccharose; ssniff order number S5745-E712) 
4) HC: high-fat diet containing 0.5 % cholic acid (ssniff order number S5745-E716) 
Cholic acid was mixed into the homogenized food powder as sodium compound [Na-Cholate: 
CAS: 361-09-1], which afterwards was pressed to feeding pellets. This procedure prevents 
demixing and assures homogenous distribution of cholic acid within the pellet. 
 
Fig. 8: Composition of experimental diets used in this thesis. The custom-made semi-purified diets 
were obtained from Ssniff Spezialdiäten GmbH, Soest, Germany: (A) C, S5745-E702, (B) CC, S5745–
E706, (C) H, S5745-E712, (D) HC, S5745–E716. Macronutrients are given in percent by weight. Weight 
of supplemented sodium cholate was equalized by the percentage weight reduction of corn starch. 
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2.3   Cholic acid supplementation in C57BL/6J and 129S6/SvEvTac mice 
Male C57BL/6J and 129S6/SvEvTac mice were assigned to one of the four diet groups (n=4-7 
per diet group) at the age of 6-7 weeks and kept at room temperature for 4 weeks. Mice were 
housed individually. Body mass and food consumption were measured twice weekly. Body 
composition (fat mass and lean mass) was determined noninvasively using the time domain 
(TD-)NMR analyzer (MQ 7.5 NMR, Minispec, Bruker Optic GmbH, Germany) at the beginning, 
as well as after 2 and after 4 weeks of experiment. Data were analyzed with the MinispecPlus 
(Bruker Optic GmbH) and OPUS (OPUS Version 5.0, Bruker Optic GmbH) software. To 
determine assimilated energy, feces was collected of all individual mice during first and fourth 
week of experiment and its energy content subtracted from energy intake. Mice were 
euthanized with carbon dioxide. Plasma samples, iBAT, iWAT and enterohepatic organs (one 
sample containing small and large intestine, caecum, liver, gall bladder and pancreas) were 
removed during dissection and weighed. As two tissue locations exist from iWAT and iBAT at 
the left and on the right side of the body, the right-sided part was fixed for histologic 
examinations (see 2.5), the left-sided part as well as plasma and enterohepatic organs were 
shock frozen using liquid nitrogen and stored at -80 °C for further analyses. 
2.4   Cholic acid supplementation in Ucp1 knockout and wildtype C57BL/6J 
mice 
In order to challenge the hypothesis, that CA-derived resistance to DIO is due to increased 
thermogenic processes in BAT, we used Ucp1 ko C57BL/6J mice for a further feeding 
experiment. As body temperature is basically maintained via thermogenic processes, which 
should not be involved in these energy expenditure investigations, all animals (both wt and 
Ucp1 ko mice) were kept at thermoneutrality (30 °C) during pregnancy, breeding and the 
experimental phase. Except surrounding temperature, and open cages instead of IVC-cages, 
animals were kept under same conditions as for earlier experiments (as described above, part 
2.1). At the age of 6 to 7 weeks, male mice were adapted to control diet for one week to 
circumvent an initial body mass drop that was observed in earlier experiments due to 
acclimatization problems to the harder texture of the semi-purified diets in comparison to 
chow diet. At the age of 7-8 weeks mice were assigned to one of the four experimental diets 
and kept at thermoneutrality for four further weeks (n=6 per group). Body mass and food 
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consumption were recorded twice weekly. At the day of diet switch (from control diet to the 
respective experimental diet) as well as after two and four weeks of experimental phase, body 
composition (fat and lean mass) was analyzed noninvasively as described above (2.3). At the 
end of the experiment, mice were euthanized with carbon dioxide. 
2.4.1   Plasma collection and blood parameter measurement  
Cardiac blood was collected from 6-8 hours fasted mice (fasting duration depended on 
dissection order) in a lithiumheparin-coated tube. The time window of blood collection did 
not exceed 2.5 hours during day time. Blood samples were centrifuged for 5 min at 2000 g. 
The plasma -appearing as supernatant- was removed, frozen in liquid nitrogen and stored 
at -80 °C. Plasma biomarker determination was performed with Piccolo Lipid Panel Plus Discs 
and the automated analyzer Piccolo xpressTM (HITADO GmbH, Germany). Thereby plasma 
concentrations of cholesterol, HDL, triglyceride, glucose as well as liver enzymes alanine 
aminotransferase (ALAT) and aspartate aminotransferase (ASAT) were determined 
simultaneously. 
2.4.2   Tissue dissection 
After blood collection iWAT, eWAT, iBAT, liver, heart and kidneys were dissected and weighed. 
As two fat tissue locations exist from iWAT, eWAT and iBAT at the left and on the right side of 
the body, the right-sided part was fixed for histologic examinations (see 2.5). The left-sided 
part as well as liver, heart and kidneys were shock frozen using liquid nitrogen and stored 
at -80 °C for further analyses.  
2.5   Tissue sample preparation for histologic analyses 
2.5.1   Tissue fixation and paraffin embedding 
Dissected tissues were fixed in 4 % paraformaldehyde solution with 0.0024 % picric acid for 
one week. Afterwards, fixated tissues were dehydrated in a series of increasing volume 
percent ethanol and xylene and infiltrated with Paraplast (Leica). 
 
MATERIAL AND METHODS   27 
 
 
 
 
Table 1: Automated dehydration steps and respective incubation times for tissue paraffin 
embedding 
Bin # Content Incubation 
 time [min] 
1 70 % EtOH 60 
2 70 % EtOH 60 
3 80 % EtOH 60 
4 80 % EtOH 60 
5 90 % EtOH 60 
6 90 % EtOH 60 
7 99 % EtOH 60 
8 99 % EtOH 60 
9 Xylene 60 
10 Xylene 60 
11 Paraplast 60 
12 Paraplast 60 
 
Afterwards, infiltrated tissue samples were paraffin embedded and cut with a rotary 
microtome (Leica). For that, about 1/3 of the tissue was discarded to reach interior tissue parts 
and be able to draw tissue-specific conclusions. Sections of 5 µm thickness were mounted on 
specimen slides (Carl Roth) and dried for 3 days at 55 °C.  
2.5.2   Hematoxylin & Eosin (H&E) staining 
For H&E staining, dried sections were transferred to a Multistainer (Leica) to ensure a 
standardized coloration. Hematoxylin and Eosin stains (Carl Roth) were used to color nuclei 
(Hematoxylin, blue stain) and cytosolic (Eosin, red/pink stain) structures. Stained sections 
were mounted in Roti-Mount (Carl Roth). 
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Table 2: Automated H&E staining steps 
Bin # Content Incubation 
 time [min] 
1 Xylene 3 
2 Xylene 3 
3 100 % EtOH 2 
4 96 % EtOH 2 
5 70 % EtOH 1 
6 distilled water 1 
7 Hematoxylin 5 
8 flow water 
station 
4 
9 Eosin 2 
10 70 % EtOH 1 
11 96 % EtOH 1 
12 100 % EtOH 1 
13 100 % EtOH 1.5 
14 Xylene 1.5 
15 Xylene 2 
16 Xylene 2 
 
2.5.3   Immunohistochemistry (IHC)  
In order to detect UCP1-positive cells, IHC staining was conducted (we were not able to 
conduct Western blots, as we used both iWAT parts for qPCR & histological analyses). For IHC 
analyses, dried H&E-stained tissue sections were heated at 70 °C for 10 min and deparaffinized 
in xylene and a decreasing ethanol gradient (99 %, 80 % and 70 %). Afterwards, sections were 
unmasked at 90 °C in 20 mM sodium-citrate for 20 min and in 10 mM sodium-citrate for 10 
min. Next, the sections were rinsed with dH2O three times, 5 min each, incubated in 3 % H2O2 
for 10 min, rinsed in dH2O for 5 min, incubated with 2.5 % blocking buffer (goat serum in PBS) 
for 1 h at room temperature and rinsed again three times for 5 min in dH2O. Sections were 
incubated overnight with 1:500 diluted primary UCP1 antibody (Abcam, ab10983) in 0.25 % 
goat serum and 0.1 % PBS-T at 4 °C. After rinsing three times 5 min each in 0.1 % PBS-T, 
sections were incubated with 1:200 diluted HRP conjugated secondary antibody (Abcam, 
ab97051) for 1 h at RT. Afterwards, sections were rinsed three times in 0.1 % PBS-T, 5 min 
each and incubated with DAB enhanced mix (Leica) for 2 min. DAB reaction was stopped by 
rinsing the sections in ddH2O. Subsequently sections were incubated for 3 min in hematoxylin 
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and rinsed with ddH2O. Sections were then dehydrated in increasing ethanol concentrates 
(70%, 96% and 100%) and xylene for 2 min each. Sections were mounted in Roti-Mount (Roth). 
2.6   Calculation of assimilated energy by balancing dietary energy intake and 
fecal energy loss 
The part of dietary energy that is absorbed in the gut and not lost with feces is called 
assimilated energy. To estimate assimilated energy, dietary energy intake was opposed fecal 
energy loss. Energy intake and energy loss are calculated by multiplying food or feces mass 
with its corresponding energy content, respectively. Energy content of food and feces samples 
was determined by bomb calorimetry analysis. For that purpose, food intake and feces mass 
was recorded as stated above (2.3). Feces was separated from litter, dried at 55 °C for at least 
one week and homogenized with a bead mill (TissueLyser II, Retsch, Qiagen, Hilden, Germany). 
Around 1 g of the homogenized feces was used to press a pellet. The exact pellet weight was 
noted. As food samples already were homogenized, a food pellet of around 1 g (the exact 
weight was noted) was used for further analysis. To analyze the energy content of food and 
feces samples, a bomb calorimeter (Calorimeter 6300, Parr, Frankfurt, Germany) was used. 
Within the bomb calorimeter, the dried sample is burned under high pressure of excess pure 
oxygen. During combustion, energy is released as heat. The induced temperature rise (ΔT) is 
measured with a thermometer and used to calculate the energy content (J/g) of the sample: 
𝐶𝑎𝑙𝑜𝑟𝑖𝑐 𝑣𝑎𝑙𝑢𝑒 (𝐽/𝑔) = 𝑊 ∗
Δ𝑇
𝐺
 
W = heat capacity of the calorimeter (J/K) 
ΔT = temperature change (K) 
G = sample weight (g) 
The heat capacity is defined as the amount of heat needed to increase the temperature of the 
entire calorimeter by 1 °C. 
2.7   Energy expenditure analysis by indirect calorimetry measurements 
Energy expenditure of mice was determined by indirect calorimetry (CaloSys SPEC, LabMaster, 
TSE Systems, Bad Homburg, Germany). In subjects with aerobic metabolism dietary nutrients 
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are converted to energy under oxygen consumption and carbon dioxide production. The 
caloric equivalent, which corresponds to the energy per liter oxygen consumed, is used to 
determine energy expenditure. Depending on the substrate that is oxidized, the caloric 
equivalent ranges from 19-21 kJ*l O2-1. 
Two weeks before experimental start and during the first two days of measurement all mice 
received the control diet to acclimate to the texture and taste of the experimental diet as well 
as the altered habitat. The diet change to either H or HC diet was conducted in the time period 
between 9 am and 1 pm (cohort 1: 9 am, cohort 2: 12 am, cohort 3: 1 pm). For indirect 
calorimetry measurements, up to eight mice were kept individually in special modified home 
cages and placed in a temperature-controlled climate chamber (Feutron) at 23 °C. Air was 
aspirated with a constant flow rate of 0.7 l*min-1. The volumes of oxygen consumed (Δvol % 
O2) and carbon dioxide produced (Δvol % CO2) were determined automatically every nine 
minutes. Mice were kept in the indirect calorimetry chamber for seven days. After 48 hours in 
the climate chamber, diet was changed to high-fat diet with our without cholic acid 
supplementation, in each case to the half of all animals. Body weight was determined at five 
specific time points:  
- Previous to indirect calorimetry measurements: 14, 7 and 2 days before diet change 
- After indirect calorimetry measurements: 5 and 8 days after diet change, which 
corresponds to the beginning and the end of the subsequent FDA measurement 
Body weight and food intake were not measured during indirect calorimetry phase, in order 
to not distort gas concentrations (overview experimental setup: see Fig. 2). 
The respiratory exchange ratio (RER) was calculated for each data point every nine minutes 
according to the following equation: 
RER = ΔCO2 [%] / ΔO2 [%] 
The RER indicates, which substrate is mainly oxidized for energy generation. It ranges within 
the limits from 1.0 (carbohydrates), 0.81 (proteins) to 0.705 (lipids) (Even and Nadkarni, 2012). 
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Oxidation of one carbohydrate molecule: 
6 O2 + C6H12O6 → 6 CO2 + 6 H2O + 38 ATP  
RERcarbohydrate = VCO2/VO2 = 6 CO2/6 O2 = 1.0 
Oxidation of one fatty acid molecule:  
23 O2 + C16H32O2 → 16 CO2 + 16 H2O + 129 ATP  
RERfatty acid: VCO2/VO2 = 16 CO2/23 O2 = 0.7 
 
MeanRER24h was assessed by calculating the mean RER value for 24 hours at the second day 
of measurement (the first day was discarded as acclimatization phase). 
The caloric equivalent (CE), which is the number of kilojoules produced per liter of oxygen 
consumed, was calculated according to the following equation: 
CE [kJ*l O2-1] = 16 + 5*meanRER24h, ad-lib 
The daily energy expenditure (DEE), which is the energy expended during 24 hours, was 
calculated according to the following equation: 
Daily energy expenditure (DEE) [J/d] = CE [k*l O2-1] * meanVO2, 24h [ml*d-1] 
Resting metabolic rate (RMR), which represents the minimum amount of energy required to 
maintain body functions at rest, under thermoneutrality (30 °C) and fasted, was calculated 
according to the following equation: 
Resting metabolic rate (RMR) [J/h] = CE [kJ*l O2-1] * VO2, rest [ml O2*h-1] 
VO2, rest was specified by selecting the lowest VO2 consumption rate during all days of measure-
ment, which normally can be found during the resting phase of the animals at day times. 
DEE and RMR were corrected for body composition. As lean mass is metabolically more active 
than fat mass, a correction formula, that involves fitting both lean mass and fat mass as 
independent variables and that weighs lean mass stronger than fat mass, was used: lean mass 
+ 0.2 fat mass (Even and Nadkarni, 2012). 
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2.8   Feeding-drinking-activity measurements 
Subsequent to indirect calorimetry measurements, mice were transferred to a feeding-
drinking-activity system (TSE Systems), where food intake and spontaneous locomotor activity 
were measured automatically. Mice were kept in type III cages (820 cm2) at room temperature 
with ad libitum access to food and water. Food intake was measured in 5-minutes intervals. 
Physical activity was identified via infrared photo sensors three-dimensionally (X, Y and Z 
directive light barriers). The first day of measurement was skipped as acclimatization phase of 
mice and analysis started at 0:00 a.m. at day 2. Food intake and activity (given as distance 
covered in meters) were analyzed cumulatively or in absolute numbers in 12-hours periods 
(light/dark phases), respectively. 
 
Fig. 9: Overview of experimental setup for indirect calorimetry and subsequent feeding-drinking-
activity measurements (C: control diet, FDA: Feeding-drinking-activity measurement, H: high-fat diet, 
HC: high-fat diet supplemented with 0.5 % cholic acid, IVC: Individually ventilated cage).  
2.9   RNA isolation from tissue samples, cDNA synthesis and quantitative real-
time polymerase chain reaction (qRT-PCR) 
Total tissue RNA was isolated by homogenizing tissue samples in 1000 μl TRIsure (Bioline) for 
20 s using an Ultra-Turrax (IKA) and incubating for 5 min at room temperature. For tissues with 
high fat content, such as iWAT or eWAT, an intermediate centrifugation step of 2500 g for 
5 min was inserted to separate the homogenate from the top lipid phase. Afterwards, the 
samples were mixed with 200 μl chloroform, incubated for further 3 min at room temperature 
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and centrifuged for 15 min, 12000 g at 4 °C. The clear top phase was mixed with 500 μl 75 % 
ethanol, transferred to columns of the SV Total RNA Isolation System (Promega) and 
proceeded according to the manual. RNA was eluted in 50 μl nuclease-free water and 
concentration was measured spectrophotometrically (Infinite® 200 NanoQuant, Tecan). RNA 
integrity was assessed on a 1.5 % DNA agarose gel (note: DNA gels were tested to assess rRNA 
samples and found to be equally suitable with RNA gels). 800 ng of isolated RNA (about 15 µl 
sample) were mixed with 10 µl nuclease free H2O as well as 5 µl loading buffer and separated 
by length on the DNA agarose gel for approximately 40 min at 100 V to visualize the 28S and 
18S rRNA bands. RNA was portioned into aliquots and stored at -80 °C.  
loading buffer (6x concentrated):  
10 mM Tris-HCl (pH 7.6), 0.2 % OrangeG, 60 % glycerol, 60 mM EDTA 
1.5 % agarose gel: 
3 g agarose, 200 ml TAE-Buffer (Roth), 10 µl Roti Safe (Roth) 
Isolated RNA was reverse-transcribed into cDNA by means of the QuantiTect® Reverse 
Transcription Kit (Qiagen), which utilizes oligo-dT and random primers in a 10 μl reaction 
mixture containing 500 ng RNA, was used. cDNA was stored at -20 °C. Primer sequences were 
designed using the Primer3 algorithm (SDSC Biology Workbench) and tested in a non-
quantitative PCR. Only primer pairs that generated a single, sharp product band were applied 
in the qRT-PCR analysis. Primers were produced by Eurofins Genomics and sequences were as 
follows:  
Ucp1: for: 5’-TCT CTG CCA GGA CAG TAC CC-3’, rev: 5’-AGA AGC CCA ATG ATG TTC AG-3’ 
Cidea: for: 5’- TGC TCT TCT GTA TCG CCC AGT-3’, rev: 5’-GCC GTG TTA AGG AAT CTG CTG-3’ 
Cox7a1: for: 5’-CCG ACA ATG ACC TCC CAG TA-3’, rev: 5’-TGT TTG TCC AAG TCC TCC AA-3’ 
Otop1: for: 5’-ACT AGG ACC CCG TCG AAT CT-3’, rev: 5’-ACC ATG CTC TAC GTG CTG TG-3’ 
Hsp90: for: 5’-AGG AGG GTC AAG GAA GTG GT-3’, rev: 5’-TTT TTC TTG TCT TTG CCG CT-3’ 
ActB: for: 5’-AGA GGG AAA TCG TGC GTG AC-3’, rev: 5’-CAA TAG TGA TGA CCT GGC CGT-3’ 
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Gene expression was determined from a standard curve consisting of pooled cDNA in 28-fold 
dilution. Expression levels of target genes were normalized to the mean of heat shock 
protein 90 (Hsp90) and beta-actin (ActB) expression. 
For analysis of gene expression, the SYBR Green-based qRT-PCR was performed either on 96-
well (Mastercycler® ep realplex epgradient S, Eppendorf) or 384-well format (Roche 
LightCycler® 480) according to tables 3 and 4. A melting curve was recorded at the end of the 
program to confirm the quality of the amplified product and identify possible non-specific 
reaction products. 
Table 3: qRT-PCR reaction mixture for gene expression analysis 
 Volume per reaction [µl] 
 96-well plate 384-well plate 
Sensimix SYBR No-ROX (Bioline) 12.5 6.25 
Primer forward 1.0 (10 pmol/µl) 1.0 (5 pmol/µl) 
Primer reverse 1.0 (10pmol/µl) 1.0 (5 pmol/µl) 
Nuclease-free water 9.5 3.25 
cDNA 1.0 1.0 
Total volume per well 25.0 12.5 
 
Table 4: qRT-PCR program for gene expression analysis 
Step Temperature [°C] Time [s]  Cycles 
Initialization 95 420   
Denaturation 97 10   
Annealing 53 15 45x 
Elongation 72 20  
Melting Curve 60 to 95 1200   
 
The samples’ gene expression range was calculated with the help of a standard curve that was 
generated from pooled, undiluted cDNA of all samples (n=48) and diluted by 2n in eight steps. 
On 96-well plates, standards and cDNAs were measured in duplicates, on 384-well format in 
triplicates. The mean expression of the technical replicates was normalized by the mean 
expression of the two housekeeping genes HSP90 and ActB. 
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2.10   Mass spectrometric analysis of bile acid composition and concentration 
2.10.1   Bile acid extraction 
Plasma 
10 µl plasma were mixed 1:2 with 10 µl of 1 µM internal standard mix (bile acids that were 
used for external and internal standards: see appendix, table 10). To extract bile acids, 500 µl 
methanol was added, mixed and centrifuged at 12000 rpm for 10 min at 4 °C. 1.5 ml 
supernatant was transferred to a new reaction tube. The solvent was evaporated in a speed 
vac (SPD111V SpeedVac, Thermo Savant) at 40 °C. The residue was resuspended in 50 µl 
methanol and 50 µl LCMS water, vortexed at 40 °C for 5 min (Thermomixer compact, 
eppendorf). 10 µl of the final analyte, which contains a bile acid proportion of plasma : internal 
standard of 1:1, was transferred to HPLC vials. 
Organs 
Enterohepatic organ samples were ground in liquid nitrogen. Bile acids were extracted out of 
40 mg tissue with 800 µl methanol. The supernatant was dried in speed vac at 40 °C. The 
extract was resuspended in 800 µl methanol. 20 µl of the resuspended extract were diluted 
1:50 with 980 µl of a methanol and water mix (1:1). 100 µl were transferred to the LCMS vial 
and 10 µl stable isotope labeled standard added. As the proportion of extract and standard 
was 1:5 in vial (2 µl extract, 10 µl standard), the final bile acid concentration results were 
multiplied by 5. 
Feces 
20 mg of dried and pestled feces were extracted twice with 800 µl methanol and mixed at 
700 rpm at 25 °C for 30 min and afterwards centrifuged at 12000 rpm for 10 min. The 
supernatant was transferred to a new reaction tube and dried in speed vac at 40 °C. The 
extract was resuspended in 1 ml methanol and diluted 1:50 (10 µl extract, 490 µl methanol). 
50 µl of the diluted extract was combined with 10 µl stable isotope labeled standards and 60 
µl LCMS water containing NH4Ac 10 mM and filtered. As the proportion of extract and 
standard was 1:10 in vial (1 µl extract, 10 µl standard), the final bile acid concentration results 
were multiplied by 10. 
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2.10.2   Analysis of bile acid concentration and composition 
The mass spectrometer (ABSciex QTrap 5500) was operated in positive mode and mass 
spectra recorded using the multiple reaction monitoring (MRM) mode. Signal acquisition was 
performed using Analyst Software and quantitation with Multiquant Software (ABSciex, 
Framingham, MA, USA). 
2.11   Blood lipids analysis 
A quantitative determination of total cholesterol (CHOL), high-density lipoprotein cholesterol 
(HDL), triglycerides (TRIG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
and glucose (GLU) in the plasma samples was conducted with Piccolo® Lipid Panel Plus Reagent 
Disc, used with the Piccolo xpress™ Chemistry Analyzer (Abaxis North America, USA). For that 
purpose, 110 µl of heparinized plasma samples were transferred to a lipid panel plus disc and 
analyzed according to the manufacturer’s protocol in the automated Piccolo Analyzer. Low-
density lipoprotein cholesterol (LDL) and very low-density lipoprotein cholesterol (VLDL) were 
automatically calculated out of the CHOL, HDL and TRIG concentrations by the analyzer.  
2.12   Bile acid transporter sequencing & in silico PCR 
RNA of enterohepatic organs (small & large intestine, liver, gall bladder) was isolated from a 
C57BL/6J as well as a 129S6/SvEvTac mouse, and qualitatively as well as quantitatively 
controlled as described in chapter 2.9 and reverse transcribed to cDNA. 
Full length primers were designed with the help of the online platforms “Ensemble genome 
browser” (http://www.ensembl.org/index.html) and “Primer3” 
(http://workbench.sdsc.edu/), to cover the full length of the gene’s coding region. 
Oligo name Forward primer sequence (5’ → 3’) Reverse primer sequence (5’ → 3’) 
ASBT ATTTGCACAGCACAAGCAGT TCTCATCAAATGATGGCCTG 
OSTb GGGCCAGAAACATCTCAATC GGGCGTTATGGGGTACTCTC 
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The PCR products were transferred to a DNA gel, generated bands were cut. Sequencing of 
the bile acid transporters Ostb (Slc51b gene) and Asbt (Alc10A2 gene) was performed by a 
commercial provider (Eurofins Genomics GmbH, Germany). 
2.13   Statistics 
Statistical analyses were performed using the software GraphPad PRISM 6, SigmaPlot 12.3 
(Systat Software Inc., San Jose CA/USA), and R (RStudio 2.14.1). Statistical tests were applied 
as specified in the respective figure legends. P-values <0.05 were considered as statistically 
significant. 
For comparison of two normally distributed groups, significance was determined using the 
two-sided Student’s t-test. Two or more normally distributed groups were compared by two-
way Analysis Of Variance (ANOVA) with respect to two variables. Related samples were 
analyzed with Sidak’s post-test for multiple comparisons. Two-Way Repeated Measures (RM) 
ANOVA and Sidak’s post-test was used to compare one variable between two groups, that was 
repeatedly measured over time. A linear regression model was applied to compare a repeatedly 
measured variable among experimental groups that differed with respect to two characteristics. 
Data adjustment was performed to remove the influence of a disruptive factor. Regression lines 
are indicated for significant correlations only. 
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3    RESULTS 
In the year 2006, Watanabe et al. described the prevention of diet-induced obesity (DIO) due 
to dietary cholic acid (CA) supplementation in C57BL/6J (BL6J) mice. They speculated that this 
phenomenon is based on a CA-derived increase of thermogenic processes in brown adipose 
tissue (BAT). However, the authors did not provide a substantive, direct proof of neither BAT 
recruitment nor UCP1 activation within this context. In order to prove their experiment’s 
reproducibility, we initially repeated the key experiment of Watanabe et al., 2006. Moreover, 
we used the Ucp1 ko mouse to directly prove the role of UCP1. 129S6/SvEvTac (129Sv) mice 
were used to investigate the role of white fat browning within this regard. With the help of 
the obtained findings, we would be able to further enlighten the underlying molecular 
mechanisms and to investigate a possible contribution of white adipose tissue (WAT) 
browning to this effect. 
Parts of this work have recently been published (Fromme et al., 2019). 
3.1   Bile acid supplementation verifiably prevents C57BL/6J mice from diet-
induced obesity 
In our study male BL6J mice at the age of 6-7 weeks were fed a control (C) or high-fat diet (H), 
or one of the two diets with CA-supplementation (CC or HC), respectively. No differences in 
food intake were observed during the complete experimental phase (Fig. 10a). As 
experimental diets varied in energy content (Table 5), animal food intake was adjusted by 
energy content (kJ/g) of the respective diet. No differences in energy intake could be detected 
between non-supplemented and CA-supplemented diet groups (Fig. 10b). Despite these 
findings, H-fed BL6J mice significantly gained more body mass compared to control fed mice 
after 28 feeding days (p=0.001), whereas HC-fed mice showed a body mass development 
comparable to C-fed mice. Notably, CA-supplementation seems to prevent diet-induced 
obesity but does not lead to body mass loss in general: it maintains normal body weight in H-
fed mice but does not further reduce body mass in C-fed mice (Fig. 10c). Thereby, a reduced 
fat mass fully accounted for the CA-mediated DIO-prevention (Fig. 10d), as lean mass was not 
affected by CA-supplementation (Fig. 10e). These observations proved the reproducibility of 
Watanabe’s key finding and provided the basis for all further investigations. 
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We observed an initial body mass drop for C, CC and HC-fed mice within the first experimental 
week (Fig. 10c). This effect presumably resulted from the diet change from chow diet to 
experimental semi-purified diet, which has a different taste and comparatively hard texture. 
The H diet instead is pleasant-tasting and its texture is soft. Moreover, the related initial body 
mass loss of HC and CC-fed mice can eventually be attributed to the bitter taste that bile acids 
possess by nature. In order to circumvent adaption difficulties to the differing texture of the 
semi-purified experimental food, an intermediate phase was included in all following feeding 
experiments, where all animals first switched to C diet for one week and afterwards received 
the respective experimental diet. 
 
Fig. 10: Cholic acid supplementation prevents diet-induced obesity in C57BL/6J mice due to fat mass 
reduction (n=4-7). Figure modified from Fromme et al. (2019). a) Cumulative food intake during 28 
experimental days. Note: Food intake of only four H-fed animals was analysed due to exclusion of three 
food spilling animals). b) Mean energy intake at experimental day 28. Differences between 
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supplemented and non-supplemented groups were t-tested. a) and b) Mean values with standard 
deviation are shown (n=4-7). c) Body mass development over 28 experimental days. CA-
supplementation effectively prevented body mass gain of H-fed BL6J mice (BA main effect p=0.0024; 
Linear Mixed Effects Model), whereas supplementing CA to C diet does not affect body mass 
development (p=0.718). Mean values with standard error bars are shown (n=6-7). d) Total fat mass at 
experimental day 28. CA-supplementation impeded H feeding derived fat mass accumulation 
(p=0.0024). e) Total lean mass at experimental day 28. d) and e) Mean values with standard deviation 
are shown (n=6-7). 
Table 5: Energy content of experimental diets analyzed by bomb calorimetry. 
Diet Energy [kJ/g] 
C 17.2 
CC 17.0 
H 20.5 
HC 21.2 
 
To consider possible effects of CA-supplementation on energy assimilation, energy contents 
of food and feces samples of experimental week 4 were analyzed by bomb calorimetry. The 
energy of high-fat diets is assimilated more effectively than energy of low fat diets. However, 
no influence of CA-supplementation on assimilated energy and assimilation coefficient was 
observed, neither on C nor on H diet (Fig. 11). Thus, differences in body mass and body 
composition between non-supplemented and CA-supplemented diets were not caused by an 
altered energy intake. 
 
Fig. 11: Assimilated energy and assimilation coefficient in BL6J mice after 28 experimental days (n=4-
7). Mean values are shown, data points represent individual animals. 
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3.2   Influence of dietary cholic acid supplementation on C57BL/6J mice 
At experimental day 28, animals were sacrificed and dissected. Amongst others, inguinal white 
adipose tissue (iWAT) and interscapular brown adipose tissue (iBAT) were weighed, the left-
sided fat pad was shock frozen for qPCR experiments, the right-sided part was fixed for H&E-
staining and subsequent microscopic analyses. 
3.2.1   Altered iBAT morphology and Ucp1 mRNA expression  
Mean total iBAT mass was significantly reduced due to CA-supplementation in H-fed mice (Fig. 
12a). This effect, however, presumably is not caused by the reduction of pure brown 
adipocytes but mainly by a reduction of the size and number of white adipocytes residing in 
iBAT. This effect was not only observed during animal dissection by comparing iBAT 
appearance visually, whereby iBAT of H-fed mice was larger and pale compared to the more 
consolidated and darker iBAT of HC-fed mice. Moreover, microscopic analyses revealed 
enlarged iBAT adipocyte sizes of H-fed BL6J mice. This effect was reversed by CA-
supplementation, as iBAT lipid storage of HC-fed mice was comparable to C-fed mice (Fig. 
12b).  
As it was hypothesized, that the DIO-protective effect of CA-supplementation to H diet is due 
to increased thermogenic processes in BL6J mice, we analyzed iBAT Ucp1 mRNA expression. 
The qPCR measurements revealed a decrease of relative iBAT Ucp1 expression in HC-fed mice 
compared to H-fed mice (p=0.0302). CA-supplementation did not affect Ucp1 expression in C-
fed mice (p=0.4862) (Fig. 12c). Therefore, we cannot confirm a CA-caused Ucp1 recruitment 
in BL6J iBAT on transcript levels. Moreover, we analyzed mRNA expression of the cAMP-
dependent thyroid hormone activating enzyme type 2 iodothyronine deiodinase (D2), as it 
was presented to be essential to the DIO-protective effect of CA (Watanabe et al., 2006). 
However, we found no effect of CA-supplementation on D2 mRNA expression (comparing 
non-supplemented with the respective supplemented diet group with Student’s t-test, data 
not shown).  
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Fig. 12: Effects of CA-supplementation on BL6J iBAT mass, morphology and Ucp1 mRNA expression 
(n=6-7). Figure modified from Fromme et al. (2019). a) Mean BL6J iBAT mass: Comparison of 
interscapular brown adipose tissue (iBAT) masses according to different diets. Mean values with 
standard deviation are shown. b) Microscopic specimen of exemplary H&E-stained iBAT tissue slides. 
Scale bar: 50 µm. c) Relative BL6J Ucp1 mRNA expression in iBAT after 28 days of experimental diet 
feeding with or without cholic acid supplementation. Ucp1 gene expression measured by quantitative 
PCR. Transcript levels were normalized to the mean expression of Hsp90 and ActB. Means are shown, 
data points represent individual animals. Statistical significance between non-supplemented and CA-
supplemented diet groups was tested using Student’s t-test. 
3.2.2   Reduced iWAT mass and potential recruitment of brite adipocytes in HC-fed 
C57BL/6J mice  
Bile acids effectively impede white adipocyte hypertrophy caused by H feeding in BL6J mice. 
Congruently to total fat mass, CA-supplementation reduced mean iWAT mass of H-fed mice 
(p<0.001) but not C-fed mice (Fig. 13a). Analyzing histologic specimens of iWAT derived from 
HC-fed BL6J mice, we did not only observe a reduced adipocyte hypertrophy, but also the 
occurrence of multilocular cells (Fig. 13b). In order to decide, whether these cells potentially 
RESULTS   43 
 
 
 
 
contribute to thermogenic processes, we analyzed the expression of the brown adipocyte 
markers Ucp1, CideA, Cox7A1 and Otop1 in BL6J iWAT using two separate two-way ANOVAs, 
for each C and H diets, with the two factors “CA-supplementation” and “gene”.  
The results of these qPCR measurements support the hypothesis that BAs cause brite 
adipocyte formation in BL6J iWAT, as CA-supplementation significantly increases brown fat 
marker expression in H-fed mice (p=0.0034). Moreover, we detected a significant interaction 
between both factors (p=0.0021), showing that the effect of CA-supplementation differs 
between the several brown fat markers of H-fed mice. In order to elucidate the strength of 
this effect on the different brown fat markers we conducted a Post-Hoc Sidak’s multiple 
comparisons test, which revealed a significant increase of Ucp1 expression due to CA-
supplementation of H diet. 
In C-fed animals, CA-supplementation did not affect brown fat marker expression, but we 
found an interaction between both factors “CA-supplementation” and “gene” (p=0.0232). 
However, this effect could not be confirmed for a single brown fat marker with Sidak’s multiple 
comparisons test (Fig. 13c). 
To corroborate these observations on protein level, we IHC-stained UCP1-positive cells in 
iWAT and observed a browning effect of HC-fed BL6J mice (Fig. 13d). With the help of IHC-
staining, we were able to proof, that the multilocular cells, which occurred in iWAT of HC-fed 
Bl6J mice, were UCP1-positive. Thus, CA-supplementation of BL6J mice in combination with a 
high-fat diet leads to a browning effect in iWAT. 
In summary, CA-supplementation significantly decreases iWAT mass, significantly increases 
brown fat marker expression and leads to recruitment of UCP1-positive multilocular cells in 
H-fed BL6J mice but has none of these effects in C-fed BL6J mice (Fig. 13). 
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Fig. 13: Effects of CA-supplementation on BL6J iWAT mass, morphology, brown adipocyte marker 
mRNA expression and occurrence of UCP1-positive cells (n=5-7). Figure modified from Fromme et al. 
(2019). a) Mean BL6J iWAT masses: Comparison of inguinal white adipose tissue masses according to 
different diets. Mean values with standard deviation are shown (n=5-7). Statistical significance 
between non-supplemented and CA-supplemented diet groups was tested using Student’s t-test. b) 
Microscopic specimen of exemplary H&E-stained iWAT tissue slides. Scale bar: 50 µm. c) Compilation 
of relative mRNA expression levels of different brown adipocyte markers in iWAT after 28 days of 
experimental diet feeding with or without CA-supplementation. Transcript levels were normalized to 
the mean expression of Hsp90 and ActB (n=6-7). Statistical significance was tested group-wise for C 
and H groups, respectively, using two-way RM ANOVA and Sidak’s multiple comparisons test for Post-
Hoc testing. d) Exemplary specimen of IHC-stained UCP1-positive cells in BL6J iWAT. Scale bar: 50 µm. 
3.2.3   Cholic acid supplementation does not increase energy expenditure 
With the help of indirect calorimetry (IC) measurements, it was possible to analyze the effect 
of CA-supplementation on energy expenditure. Therefore, IC measurements were performed 
with a further cohort of male BL6J mice. Twenty-two animals were set on control diet at the 
age of 4-5 weeks. After 12 days on C diet, the animals were singly caged and carried over into 
the indirect calorimetry measurement chamber for two further days on C diet, to adapt to the 
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climate chamber. Afterwards, at the age of 6-7 weeks (which corresponds to the age of the 
mice of the initial experiment) the animals were assigned to either H or HC group (n=11). After 
five consecutive measurement days on the experimental diets, the animals switched to a 
feeding-drinking-activity (FDA) measurement system for further 3 days (experimental design: 
see Fig. 9). All animals had free access to food and water during the whole experimental phase. 
The animals were randomly assigned to one of the two diet groups. Before the switch from C 
to H/HC diet, both diet groups did not significantly differ in mean body mass (p=0.98, Student’s 
t-test). After diet change mean body mass significantly differed between the two groups 
already after 5 days (p<0.001). This difference persisted after transferring the mice from 
indirect calorimetry to FDA device (p<0.01) (Fig. 14). 
 
Fig. 14: Absolute body mass of BL6J mice during IVC housing (days -14 to -2) and indirect calorimetry 
(days -2 to 0) on C diet as well as on indirect calorimetry (days 0 to 5) and feeding-drinking-activity 
measurements (days 5 to 8) on H or HC diet, respectively (n=11). Means with standard deviation are 
shown. Two-way RM ANOVAs were used for statistical testing. 
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Food intake did not differ between the groups at all time points during the experiment (Fig. 
15). 
 
Fig. 15: Food intake of BL6J mice during IVC housing (days -14 to -2) and indirect calorimetry (days -
2 to 0) on C diet as well as on indirect calorimetry (days 0 to 5) and feeding-drinking-activity 
measurements (days 5 to 8) on H or HC diet, respectively (n=11). Means with standard deviation are 
shown. Two-way RM ANOVAs were used for statistical testing. Note: Standard deviation of food intake 
mass of period 0 to 5 was comparatively high due to food spilling animals. Excluding spilling animals 
from statistical testing does not alter food intake comparability between both diet groups. 
Fat and lean mass were determined before (at day -2) and after (at day 5) indirect calorimetry 
measurement via NMR spectrometry (Fig. 16, experimental design: see Fig. 9). The high-fat 
diet-induced increase in fat mass was prevented by CA-supplementation, two-way RM ANOVA 
analyses of fat masses before and after indirect calorimetry (factor “time-point”) revealed a 
significant variation due to CA-supplementation (factor “diet”) of H-fed BL6J mice (p=0.0045), 
as well as a significant interaction between time-point and diet (p<0.0001). Sidak’s multiple 
comparisons testing identified a significant reduction of HC-fed mice’s fat mass, five days after 
diet change (“after IC”), as H-fed mice gained 1.5 g fat mass, but HC-fed mice did not 
accumulate further adipose tissue.) No fat mass difference was detected between both diet 
groups before IC.  
H-fed mice also gained lean mass, probably in line with the higher weight of fat mass they had 
to cope with (Fig. 16). Two-way RM ANOVA analysis of lean mass before and after indirect 
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calorimetry (factor “time-point) revealed a significant variation due to CA-supplementation 
(factor “diet”) of H-fed BL6J mice (p=0.0235), as well as a significant interaction between time-
point and diet (p=0.0008). Sidak’s multiple comparisons testing identified, that lean mass was 
significantly increased in H-fed BL6J mice after IC, as they gained 1.5 g of lean mass during IC 
measurement, whereas HC-fed mice did not. These results are comparable to the results 
obtained in earlier experiments. 
 
Fig. 16: Fat mass and lean mass before and after indirect calorimetry measurements (at day -2 and 
day 5 of experiment) (n=11). Figure modified from Fromme et al. (2019). Values are means with 
standard deviation. Body composition was assessed via NMR spectrometry (Minispec, Bruker). Two-
way RM ANOVAs were used for statistical testing. 
Energy expenditure analysis 
Analyzing the indirect calorimetry results, both groups on C diet show parallel mean 
respiratory exchange ratios initially (Fig. 17). During dark phase from 5 pm (17:00) to 5 am 
(5:00) the mean RER is kept at levels around 1.0 and starts to fall at late dark phase. During 
light phase from 5 am (5:00) to 5 pm (17:00) mean RER initially falls and finally reaches lowest 
values around 0.8 at 10-12 am. After that, RER rises again constantly and reaches levels around 
1.0 in the following dark phase. At time points where RER exceeds 1.0, animals probably 
exercised intensely, CO2 production by the working muscles rises. All mice displayed the 
typical circadian rhythm of nocturnal activity accompanied by high heat production and 
preferred carbohydrate usage as compared to lower heat production and preferred lipid usage 
during daytime at rest. 
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However, after switching the diet from C to H or HC, respectively, RER courses alter and clearly 
differ between diet groups at a progressive rate. In contrast to C-feeding, RER of H-fed mice is 
flattened with far lower peaks during active phases. They only reach levels between 0.9 at the 
beginning of dark phase and 0.8 at the beginning of light phase. This curve progression is 
typical for H feeding, as animals primarily metabolize lipids but not carbohydrates. HC fed mice 
however show phases during light phase, where very low RER levels, partly below 0.8 are 
reached for several hours. Moreover, the whole RER course seems to be shifted in comparison 
to H-fed mice. Especially from day two after diet change on, clear differences between diet 
groups were observed. HC-fed animals did not only maintain RER levels of around 0.8 during 
light phase, they also reach RER values of about 0.9 around two hours later compared to their 
H-fed mates (around 17:00 for H-fed mice, 19:00 for HC-fed mice) (Fig. 17). These observations 
suggest, that HC-fed mice either start feeding at later time-points compared to H-fed mice, 
probably due to unfavorable flavor of CA, which is known to exhibit a bitter taste, or that CA-
supplementation leads to an altered metabolism, where lipid metabolism is prolonged and 
the change to carbohydrate metabolization is delayed. Differences in RER between the 
supplemented and the non-supplemented diet group appeared rapidly after diet change and 
were thus not secondary to changes in body mass and composition. 
 
Fig. 17: Mean RER over one week, before and after diet change from C to H or HC diet, respectively 
(n=11). Figure modified from Fromme et al. (2019). 
Contradicting to our hypothesis, calculations of mean energy expenditure revealed decreased 
rates for HC-fed mice compared to H-fed mice. Both H and HC-fed mice showed highest energy 
expenditure levels at the beginning of dark phase, as they are comparatively active directly 
after resting phase, typically start searching for food and show increased food intake. Energy 
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expenditure slightly decreases during dark and active phase (17:00-5:00). H-fed animals 
seemed to expend slightly more energy compared to HC-fed during dark. This difference 
distinctly appears during light, resting phase (5:00-17:00), where HC-fed animals constantly 
expended less energy (HC: ~2.9 Watt compared to H: ~3.3 Watt) (Fig. 18). 
 
Fig. 18: Mean energy expenditure over one week, before and after diet change from C to H or HC 
diet, respectively (n=11). Figure modified from Fromme et al. (2019). 
With the help of IC and FI data, we were able to balance energy over two days of C feeding 
(days -2 to 0) as well as five days of H and HC feeding (days 0 to 5). FI (g/d) was multiplied by 
energy content of respective diet type (C: 17.2 kJ/g before diet change, and H: 20.5 kJ/g or HC: 
21.2 kJ/g after diet change). Approximately half of all animals spilled food (probably due to 
single caging). Therefore, we conducted energy balance calculations twice. Calculations 
including all animals resulted of a positive energy balance before and after diet change. There 
were no differences in mean energy intake or energy expenditure during C feeding (Figs. 19a 
and 19b). After diet change to H or HC diet, respectively, two-way RM ANOVA revealed a 
significant increase of energy intake after diet change to H diets (p=0.0002), as well as a 
significantly higher energy intake of HC-fed compared to H-fed BL6J mice (p=0.0443). Energy 
expenditure also was significantly increased after diet change to H or HC diet (p<0.0001). 
Besides, we fund a significant interaction between both factors “time” and “CA-
supplementation” (despite no effect for CA-supplementation alone) (p= 0.0061). Sidak’s 
multiple comparisons testing showed a significant difference between CA-supplemented and 
non-supplemented H diet after diet change. As HC fed BL6J mice exhibited an increased energy 
intake, but a decreased energy expenditure compared to H-fed animals, the positive energy 
balance was significantly greater in these animals (p=0.0317) (Fig. 19c). These results 
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contradict body mass observations, at which body mass was significantly reduced by HC-
feeding. 
 
Fig. 19: Energy intake (kJ/d), energy expenditure (kJ/d) and their respective delta, before (days -2 to 
0) and after diet change (days 0 to 5) during IC measurements, including spilling animals (n=11). 
Figure modified from Fromme et al. (2019). Two-way RM ANOVAs were used for statistical testing. 
As these calculations were adulterated due to spilling animals, we exemplary excluded food 
intake data of these animals (spillage limit was set to a food consumption of >5g/d). By 
extracting these data, neither mean energy intake (p=0.9196), nor delta energy (p=0.3537) 
differed between H and HC-fed animals, anymore. Energy expenditure was not altered, as it 
is not affected by food spillage (Fig. 20). 
 
Fig. 20: Energy intake (kJ/d) (n=3-9), energy expenditure (n=11) and their respective delta (n=3-9), 
before (days -2 to 0) and after diet change (days 0 to 5) during IC measurements, excluding spilling 
animals. Figure modified from Fromme et al. (2019). Student’s t-tests were applied to compare H to 
HC diet group after diet change. 
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Calculations of daily energy expenditure (DEE) and resting metabolic rate (RMR) revealed 
similar results: Both mean DEE and mean RMR did not differ between groups before diet 
change but increased due to H feeding and decreased due to CA-supplementation in the HC 
diet group, respectively. Both DEE and RMR significantly differed between non-supplemented 
and CA-supplemented H diets (Figs. 21b and 22b). 
As H-fed animals significantly gained body mass during five days of indirect calorimetry 
measurements, we adjusted both DEE and RMR, respectively for body composition according 
to the formula LM + 0.2 FM (Even and Nadkarni, 2012) in order to accommodate for the 
different body compositions of both diet groups. 
Both DEE and RMR significantly correlated with adapted body composition. As both DEE and 
RMR fitted to the regression line, H-fed animals seemingly just adapted their energy 
metabolism appropriate to their higher body mass. After body composition adjustment, both 
DEE and RMR did not differ between diet groups (Figs. 21 and 22). Consequently, we can 
conclude that any variations for DEE and RMR are due to body mass differences between diet 
groups. 
DEE and RMR adjustment was additionally done for full body mass in comparison to the body 
mass correction formula LM + 0.2 FM (data not shown). Both types of calculation yielded the 
same result, leaving the basic statement identical. 
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Fig. 21: Daily energy expenditure of H and HC-fed BL6J mice (n=11). Figure modified from Fromme 
et al. (2019). a) Body composition according to correction formula (LM + 0.2 FM) after five days on H 
or HC diet, respectively. b) Mean daily energy expenditure before (C) and after (H or HC) diet change. 
a) and b) Means with standard deviation are shown. c) Scatterplot showing a significant correlation of 
DEE and corrected body composition. d) DEE adjusted for corrected body composition. Both diet 
groups exhibit a comparable DEE, adapted to different body compositions. Mean values are shown, 
data points represent individual animals. 
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Fig. 22: Resting metabolic rate of H and HC-fed BL6J mice (n=11). Figure modified from Fromme et 
al. (2019). a) Body composition according to correction formula (LM + 0.2 FM) after five days on H or 
HC diet, respectively. b) Mean resting metabolic rate before (C) and after (H or HC) diet change. a) and 
b) Means with standard deviation are shown. c) Scatterplot showing a significant correlation of RMR 
and corrected body composition. d) RMR adjusted for corrected body composition. Both diet groups 
exhibit a comparable RMR, adapted to different body compositions. Mean values are shown, data 
points represent individual animals.  
Feeding-drinking-activity-measurements 
Subsequent to indirect calorimetry measurements, animals were transferred to the FDA 
measurement system in order to automatically measure food intake as well as physical activity 
in 5-minutes intervals per animal (drinking frequency was not observed within this setting). 
Mice were kept in the FDA measurement system at room temperature (22 ± 1 °C) on a 12 
hours light/dark cycle and were further fed their respective experimental diet, which they 
were assigned to (H or HC diet, ad libitum) for 3 days. The first day was used for acclimatization 
of animals and therefore all measurements discarded. Measurement analyses were started 
with the first light phase at day 2. 
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Both non-supplemented and CA-supplemented groups showed similar cumulative food 
intakes. During the first 12 hours of light phase HC-fed mice showed a slightly reduced 
cumulative food intake compared to H-fed mice. At the end of the first light phase the HC-fed 
mice ate significantly less compared to H-fed mice. During dark phase however, HC-fed mice 
absolutely ate more than H-fed mice, so cumulative food intake was comparatively similar for 
both diet groups at the end of the first day. During the second light phase, cumulative food 
intake stayed fairly constant for both groups, so no differences were observed for absolute or 
cumulative food intake between both diet groups. During second dark phase however, HC-fed 
mice significantly ate more compared to H-fed mice. This difference however was not 
significant when cumulative food intake was examined. In summary, HC-fed mice seem to eat 
more during dark phases when they are active. However, this difference is compensated 
during light phases, in which H-fed mice eat more (Fig. 23). In order to verify these results, 
longer measurement periods of several days have to be performed and an overestimation of 
food intake due to spilling needs to be controlled. 
 
Fig. 23: Cumulative and absolute food intake of H and HC-fed BL6J animals during FDA-
measurements over 48 hours (n=11). Food intake was compared between diet groups for every time-
point separately with Student’s t-test. Values are means with standard deviation. 
Feed consumption of individual animals was comparatively high due to spillage. Therefore, 
energy could not be balanced perfectly. Nevertheless, energy expenditure measurements (as 
follows) provided clear evidence. 
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Activity rate was determined by measuring the distance that all mice covered during the 
second and third day after transferring them to the FDA system. Analysis of absolute distance 
showed no significant difference between the diet groups, whereas HC-fed mice tend to run 
longer distances, however statistically not significant (Fig. 24). Analysis of cumulative distance 
only was significant at the end of dark phase one, 24 hours after start of measurement. 
 
Fig. 24: Cumulative and absolute distance, that H and HC-fed BL6J animals covered during FDA-
measurements over 48 hours (n=11). Food intake was compared between diet groups for every time 
point separately with Student’s t-test. Values are means with standard deviation. 
All results from IC and FDA system measurements suggest, that the CA-derived DIO-resistance 
of BL6J mice is not due to increased energy expenditure. Energy expenditure was rather 
decreased due to HC feeding. This effect however was merely caused by an adaption to a 
decreased body mass, as it disappeared after adjusting energy expenditure data to body 
composition. 
3.3   Influence of dietary cholic acid supplementation on 129S6/SvEvTac mice 
It was hypothesized, that body mass changes in BL6J mice could also result of brite adipocyte 
recruitment by CA-supplementation. 129S6 mice were used to verify this hypothesis. The 
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129S6 mouse strain is well known for its high capacity to recruit brite adipocytes. If CA-
supplementation really affects body mass by brite adipocyte recruitment and enlargement of 
thermogenic capacity, stronger effects of CA-supplementation on body mass development 
were expected in 129S6 mice. 
Mice of the 129S6 strain were kept and fed similar and in parallel to BL6J mice. At the age of 
6-7 weeks mice received a diet switch from standard chow to the respective experimental 
diet. The animals received C or H diet either with or without 0.5 % CA-supplementation and 
were kept for four weeks on the experimental diet. Body mass and food intake were recorded 
twice a week. After 28 days mice were dissected and different tissues sampled for further 
analyses (at the same time and identical to BL6J mice). 
3.3.1   Bile acid supplementation does not alter 129S6/SvEvTac body mass 
Comparable to BL6J mice, 129S6 mice showed mean food as well as energy intakes, which 
were not affected by CA-supplementation (Figs. 25a and 25b). All diet groups continuously 
gained body mass (in accordance with age specific development) and H-fed 129S6 mice gained 
significantly more body mass compared to C-fed mice (p=0.047). In contrast to BL6J mice, CA-
supplementation did not affect body mass of 129S6 mice, neither of C-fed nor H-fed mice (BA 
main-effect p=0.3925). Mean body mass of CA-supplemented and non-supplemented animals 
never differed significantly during the whole experimental phase (Fig. 25c). 
Concordant with body mass development, no differences were observed in fat mass between 
control groups and supplemented diet groups: CA-supplementation did not influence body 
mass in both C and H diets and did not reduce fat mass of H-fed mice (Fig. 25d), as detected 
in BL6J mice. Furthermore, no differences between CA-supplemented and non-supplemented 
animals were seen in lean mass at the end of experiment (Fig. 25e). 
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Fig. 25: Cholic acid supplementation has no influence on 129S6 body mass or composition (n=4-6). 
Figure modified from Fromme et al. (2019). a) Cumulative food intake during 28 days. b) Mean energy 
intake at experimental day 28. Differences between supplemented and non-supplemented groups 
were t-tested. a) and b) Mean values with standard deviation are shown. c) 129S6 body mass 
development after diet change. CA-supplementation does not affect 129S6 body mass development 
(BA main effect p=0.3925; Linear Mixed Effects Model). Mean values with standard error bars are 
shown. d) and e) Mean values with standard deviation are shown. 
Similar to BL6J mice, energy intake (Fig. 25b), assimilated energy as well as assimilation 
efficiency (Fig. 26) were slightly increased in both H compared to C-fed groups, but CA-
supplementation did not affect energy assimilation or assimilation coefficient, respectively, in 
129S6 mice (Fig. 26). 
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Fig. 26: Assimilated energy and assimilation coefficient in 129S6 mice after 28 experimental days 
(n=4-6). Mean values are shown, data points represent individual animals. Student’s t-tests were 
applied to compare non-supplemented to CA-supplemented diets. 
3.3.2   No influence on neither iBAT nor iWAT mass, morphology or brown fat 
marker mRNA expression, respectively 
Mean iBAT mass of 129S6 mice was higher in H-fed mice compared to C-fed mice (p=0.0182). 
However, CA-supplementation did not alter iBAT mass in 129S6 mice (Fig. 27a). Microscopic 
analyses of 129S6 iBAT specimen revealed, that the increase of iBAT mass due to H feeding is 
mainly caused by the increase of lipid accumulation within adipocytes. This effect is not 
prohibited by CA-supplementation, as it was observed in BL6J mice (Fig. 27b). 
Relative iBAT Ucp1 expression was not affected by CA-supplementation (Fig. 27c). Moreover, 
no differences between CA-supplemented and non-supplemented 129S6 animals were 
detected for relative iBAT Cox7a1, CideA, or Otop1 expression (not shown). 
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Fig. 27: 129S6 iBAT analyses (n=4-6). Figure modified from Fromme et al. (2019). a) Mean iBAT mass 
after 28 experimental days. CA-supplemented groups were compared to non-supplemented diets 
using Student’s t-test. Means with standard deviation are shown. b) Exemplary iBAT specimen taken 
from 129S6 mice after 28 experimental days. H&E staining, scale bar 50 µm. c) Relative Ucp1 mRNA 
expression after 28 experimental days. Means are shown, data points represent individual animals. 
Congruently, iWAT mass was increased due to H feeding (p=0.0155), however not affected by 
CA-supplementation (Fig. 28a). iWAT adipocyte morphology did not obviously differ between 
diet groups. Adipocyte size was not (as obviously as in BL6J mice) altered by different diets or 
CA-supplementation. The observed H diet-caused increase of iWAT mass did not seem to 
result in adipocyte hypertrophy primarily (Fig. 28b). Eventually adipocyte hyperplasia 
accounted for iWAT mass increase in H-fed mice. This hypothesis however was not 
investigated within this study. 
Quantitative PCR analyses of brown adipocyte marker expression in 129S6 iWAT did not show 
a specific trend towards gene expression alterations due to CA-supplementation (Fig. 28c). As 
for BL6J mice, C and H groups were compared separately using two separate two-way 
ANOVAs, for each C and H diets, with the factors “CA-supplementation“ and “gene”. 
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In contrast to BL6J mice, CA-supplementation did not affect brown fat marker expression in 
H-fed animals. The same results were obtained for the C diet group.  
 
Fig. 28: 129S6 iWAT analyses (n=4-6). Figure modified from Fromme et al. (2019). a) Mean 129S6 
iWAT masses after 28 experimental diets. Mean values with standard deviation are shown. Statistical 
significance between non-supplemented and CA-supplemented diet groups was tested using Student’s 
t-test. b) Exemplary 129S6 iWAT specimen after 28 experimental diets. H&E stains, scale bar 50 µm. 
c) Compilation of relative mRNA expression levels of different brown adipocyte markers in iWAT after 
28 days of experimental diet feeding with or without CA-supplementation. Transcript levels were 
normalized to the mean expression of Hsp90 and ActB. Statistical significance was tested group-wise 
for C and H groups, respectively, using two-way RM ANOVA and Sidak’s multiple comparisons test for 
Post-Hoc testing. 
We can conclude that the CA-derived prevention of DIO is strain specific. Moreover, there is 
a strain specific difference between BL6J and 129S6 mice concerning the influence of CA-
supplementation on iWAT morphology and iWAT brown fat marker expression. With the help 
of this result, we further studied the different mouse strains to narrow down the relevant site 
of action by successive strain comparisons. 
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3.4   Searching for the relevant strain difference 
3.4.1   Bile acid transporter sequencing 
The data we have raised did not argument for a decreased food intake, which might have 
accounted for a body mass drop of HC-fed animals. As food intake seemed to be unchanged 
by CA-supplementation, we investigated subsequent sites of action that might account for the 
observed strain differences between BL6J and 129S6 mice. 
In order to elucidate the strain specific variations, we initially sequenced the genes of the two 
BA transporters apical sodium dependent bile acid transporter (ASBT), and organic solute 
transporter β (OSTb) that are responsible for the uptake of BAs from gut and their efflux to 
portal blood. 
The ASBT transporter is located at the terminal ileum, where it is responsible for the uptake 
of BAs from the gut lumen into enterocytes. The coding region of the corresponding gene was 
sequenced in large parts (codons for >320 amino acids). However, the start codon and the 
codons for the first eight amino acids as well as the stop codon and the codons for the last 20 
amino acids were missing. Within the sequenced region ten stem specific differences were 
identified. Five of these nucleotide sequence differences lead to stem specific differences in 
amino acid sequence, whereby three of those are located N-terminal within a region of only 
12 amino acids. 
The OSTb transporter is primarily located at the basolateral membrane of enterocytes from 
the ileum and responsible for the efflux of bile acids into portal blood (as heteromer in 
interaction with OSTa). The coding region of the OSTb transporter gene was sequenced 
completely. Sequencing revealed one single strain specific position, which is known as 
rs29931408. A nucleotide replacement C/A leads to an amino acid switch of Q (glutamine) to 
A (alanine). 
Accordingly, these two transporters are prime candidates to further investigate the strain 
specific phenotypic differences that were observed after CA-supplementation of H diet. 
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3.4.2   Balancing bile acid levels in C57BL/6J and 129S6/SvEvTac mice 
In contrast to mice of the C57BL/6J strain, 129S6/SvEvTac mice did not react to dietary cholate 
supplementation in any parameter measured in this study. To clarify whether this discrepancy 
is caused by differences in intestinal bile acid absorption, metabolism or tissue sensitivity, we 
determined BA concentration and composition in several organismic compartments.  
As food intake did not differ between strains and was not influenced by CA-supplementation, 
CA intake also was expected to be similar between diet groups as well as strains. CA was mixed 
into food pellets by a specialized food manufacturer (Ssniff), who guarantees for homogenous 
distribution of CA within the food pellets as well as prevention of demixing or separation. Both 
mouse strains were fed with pellets of the same batch. As food intake was comparable 
between strains and diet groups, the calculated CA intake amounts to averagely 40 µmol/day 
in all supplemented groups (Table 6, Fig. 29). 
Calculation of mean CA intake [µmol/day]: 
Mean food intake [g*day-1] * 0.005 (CA percentage in CC and HC diet) * 408.58 [g*mol-1]-1 
(molecular weight of CA)*106. 
Table 6: Mean daily food intake (n=4-7). 
 
 
In plasma, organ and feces samples, bile acids were mass spectrometrically quantified and 
qualified by using radiolabelled standards. With this procedure, the 17 physiologically most 
abundant bile acids could be detected (15 single BAs +2 groups of murine BAs) in plasma. Due 
to supply difficulties, fewer standards were available during subsequent BA analysis in organs 
and feces: Nine single BAs and the two BA-groups could be detected in enterohepatic organs 
Fig. 29: Calculated cholic acid intake (n=4-7). 
Figure modified from Fromme et al. (2019). 
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and 13 single BAs and the two BA-groups in feces. The amount of total BAs was calculated by 
adding masses of individual BAs. 
Plasma 
The quantified plasma BA levels were adjusted to the calculated individual plasma volume of 
each animal. Therefore, the following plasma BA concentrations relate to total plamsa levels 
within experimental animals. 
Plasma BA levels of BL6J mice were massively increased due to CA-supplementation, both in 
C diet group (14-fold increase) and in H diet group (45-fold increase). In 129S6 mice, this 
increase was only seen in C-fed animals, as their mean plasma BA level was raised 53-fold, but 
was not in H-fed animals.  
In plasma of C-fed BL6J mice, a more than 10-fold higher BA level was found compared to C-
fed 129S6 mice (BC/SC=15.8 µM/1.4 µM). This difference could hint at a generally higher BA 
concentration in BL6J plasma compared to 129S6 mice. This strain difference was not 
observed in the H-fed group, as one SH animal exhibited extraordinary high plasma BA levels. 
Without this animal, H-fed BL6J animals would have shown 4.4-times higher BA plamsa levels 
compared to 129S6 mice. Bile acid concentration in H-fed BL6J (BH) mice was approximately 
70 % less than their C-fed (BC) counterparts (BC/BH=15.8 µM/4.4 µM). This difference was 
also mainly caused by a single C-fed BL6J animal. Removing this animal would lead to similar 
BA levels in BC and BH mice. BL6J mice seem to naturally have higher plasma BA levels 
compared to 129S6 mice, except during H diet, where we found similar mean BA levels for 
both strains. 
Notably, there have been individual mice, that showed exceptional high plasma BA levels, 
which were much higher compared to their counterparts of the same diet and strain. For 
example, one H-fed 129S6 animal had 20-fold higher plasma BA levels compared to the other 
H-fed 129S6 mice. Without this animal, we would also have seen an increase of BA levels due 
to CA-supplementation in H-fed 129S6 animals, as well as a difference of H-fed BL6J mice 
compared to 129S6 mice (Table 7, Fig. 30). 
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Table 7: Plasma BA levels (n=4-7). 
Diet Strain 
Mean plasma bile 
acid levels [µM] 
 
B 15.8 
S 1.4 
CC 
B 227.6 
S 37.6 
H 
B 4.4 
S 5.0 
HC 
B 196.1 
S 4.8 
 
 
In order to receive statistical evidence, we used two separate two-way ANOVAs for each C and 
H diet group separately with the two factors “CA-supplementation” and “strain”. (As no 
matched data was imposed, like in analyses of e.g. gene expressions, Post-Hoc testing was not 
conducted.) 
Plasma BA levels of all C-fed animals of both strains neither showed a statistically significant 
strain effect nor an influence of CA-supplementation. 
In contrast to this, plasma BA levels of H-fed animals were significantly increased due to CA-
supplementation (p=0.0088). Moreover, strains significantly differed in H diet groups 
(p=0.0090), with BL6J mice showing a higher plasma BA concentration compared to 129S6 
mice, above all with CA-supplemented H diet. We also detected a significant interaction 
between both factors (p=0.0087) in this group, confirming a higher plasma BA-raising effect 
for supplemented H-fed BL6J compared to 129S6 animals. 
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Fig. 30: Plasma bile acid concentration [µM] on log-scale, analyzed by HPLC/MS quantification (n=4-
7). Figure modified from Fromme et al. (2019). Means are depicted on log-scale, data points represent 
individual animals. Statistical analyses were conducted using separate two-way ANOVAs for C and H 
diets, with the two factors “CA-supplementation” and “strain”. C diets: no effect due to CA-
supplementation, no strain effect. H diets: effect due to CA-supplementation (p=0.0088), strain effect 
(p=0.0090), and strain-diet-interaction (p=0.0087). 
In conclusion, BL6J mice generally exhibit higher plasma BA levels compared to 129S6 mice. 
Plasma BA levels were found to be influenced by both CA-supplementation and strain, 
respectively, in H diet groups.  
Enterohepatic organs 
For BA analyses in organs, mice were dissected and all organs that are part of the 
enterohepatic circulation (including small and large intestine, caecum, liver, and gall bladder; 
collectively called enterohepatic organs (EO) in the following) were removed, shock frozen in 
liquid nitrogen, homogenized and processed for HPLC analysis as described above (see 
paragraph 2.10). As hypothesized, BA pool was enlarged in CA-supplemented animals 
compared to non-supplemented animals. BL6J mice naturally show higher BA pool sizes 
compared to 129S6 mice, with C-fed 129S6 mice having only an organ BA pool size of 55 % 
compared to C-fed BL6J mice and 42 % in H-fed animals. H-feeding slightly increases organ BA 
pool size in in BL6J animals but not in 129S6 animals.  
Despite equal CA-uptake with food, supplemented 129S6 mice showed a far less BA pool size 
compared to BL6J mice (CC: 78 % less, HC: 67 % less). Due to CA-supplementation, 129S6 mice 
only reach organ BA pool concentrations that are comparable to BL6J organ BA pool 
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concentrations without CA-supplementation. Moreover, the fold-change of mean organ BA 
pool due to CA-supplementation is higher in BL6J (C → CC: 5.3-fold, and H → HC: 3.5-fold) 
compared to 129S6 mice (C → CC: 2.2-fold and H → HC: 2.7-fold) (Table 8). 
Table 8: Mean BA pool [µmol/animal] in enterohepatic circulation of BL6J and 129S6 mice, 
adjusted to individual EO weight. 
Diet Strain 
Mean organ BA 
pool 
[µmol/animal] C B 5.3 
S 2.9 
CC 
B 28.1 
S 6.3 
H 
B 7.3 
S 3.1 
HC 
B 25.5 
S 8.4 
 
Statistical analyses were also conducted using two separate two-way ANOVAs for each C and 
H diet group separately with the two factors “CA-supplementation” and “strain”. 
In both diet groups, EO BA concentration significantly differed due to CA-supplementation (C: 
p<0.0001, H: p<0.0001), with higher BA concentrations in CA-supplemented diet groups. 
Moreover, EO BA concentration significantly differed between strains in both diet groups (C: 
p<0.0001, H: p<0.0001). We also found a significant strain-diet-interaction in both diet groups 
(C: p<0.0001, H: p=0.0016), demonstrating a stronger BA pool raising effect in supplemented 
BL6J compared to 129S6 animals (Fig. 31). 
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Fig. 31: Bile acid concentration [nmol/mg] in enterohepatic organs, analyzed by HPLC/MS 
quantification (n=4-7). Figure modified from Fromme et al. (2019). Means are depicted, data points 
represent individual animals. Statistical analyses were conducted using separate two-way ANOVAs for 
C and H diets, with the two factors “CA-supplementation” and “strain”. C diets: effect due to CA-
supplementation (p<0.0001), strain effect (p<0.0001), strain-diet-interaction (p<0.0001). H diets: 
effect due to CA-supplementation (p<0.0001), strain effect (p<0.0001), strain-diet-interaction 
(p=0.0016). Cave: Not all BAs that were quantified in plasma were also quantified in EO (missing bile 
acids: Dehydro-CA, CDCA, UDCA, GCDCA, GUDCA, TUDCA). 
Feces 
To estimate daily fecal bile acid loss, excreted feces mass was determined and its BA 
concentration analyzed using HPLC/MS. For that, feces were sampled at week four of 
experiment for three days, pooled, homogenized and processed for HPLC/MS analysis as 
stated above (methods, paragraph 2.10.1). 
The total amount of BAs in feces was drastically increased by CA-supplementation. The 
observed strain difference in plasma and organ BA concentrations could also be seen in fecal 
bile acid concentrations, as 129S6 mice exhibited slightly lower BA concentrations (statistically 
significant for C/CC-fed animals) (Table 9, Fig. 32). 
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Table 9: Mean fecal bile acid excretion [µmol/g] of BL6J and 129S6 mice. 
Diet Strain 
Mean fecal BA 
excretion [µmol/g] 
C 
B 6.2 
S 4.8 
CC 
B 69.0 
S 46.2 
H 
B 17.7 
S 7.9 
HC 
B 73.5 
S 68.3 
 
For statistical analyses we pooled animals of both strains and conducted two-way ANOVAs for 
each diet group separately: BA excretion significantly differs between strains in C diet groups 
(p=0.0074), with 129S6 animals excreting less BAs compared to BL6J animals. Moreover, we 
found a statistically significant increase of fecal BA excretion due to CA-supplementation 
(p<0.0001) as well as a significant interaction between both factors (p=0.0150), hinting at a 
stronger increase in BA excretion due to CA-supplementation in BL6J animals. Additionally, 
CA-supplementation also significantly increases BA excretion in H-fed animals (p<0.0001). In 
contrast to C-fed mice, we did not observe a strain difference in H diet groups (Fig. 32).  
As there were no differences in feces mass between strains or diet groups, similar results were 
obtained for daily fecal BA excretion mass (not shown). 
 
Fig. 32: Fecal bile acid excretion [µmol/g], analyzed by HPLC/MS quantification (n=4-7). Figure 
modified from Fromme et al. (2019). Means are depicted, data points represent individual animals. 
Statistical analyses were conducted using separate two-way ANOVAs for C and H diets, with the two 
factors “CA-supplementation” and “strain”. C diets: effect due to CA-supplementation (p<0.0001), 
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strain effect (p=0.0074), and strain-diet-interaction (p=0.0150). H diets: effect due to CA-
supplementation (p<0.0001). Cave: Not all bile acids that were quantified in plasma were also 
quantified in EO (missing bile acids: Dehydro-CA, TCDCA). 
Bile acid composition 
Bile acid composition is compartment (feces, enterohepatic organ, plasma) specific and similar 
in both strains (Fig. 33). Interestingly, despite differences in absolute plasma concentration 
(Fig. 30), the contribution of individual bile acids to the total pool was comparable in both 
strains and differed only as a consequence of supplementation and compartment (feces, 
enterohepatic organ, plasma) (Fig. 33). 
 
Fig. 33: Composition of bile acid pools in feces, enterohepatic organs and plasma (n=4-7). Figure 
taken from Fromme et al. (2019). Every bar section represents the median molar concentration as a 
fraction of total pool size. CA: cholate, DCA: deoxycholate, TCA: taurocholate, GDCA: 
glycodeoxycholate, LCA: lithocholate, TCDCA: taurochenodeoxycholate, TDCA: taurodeoxycholate, 
wMCAs: omega-muricholates, CDCA: chenodeoxycholate, UDCA: ursodeoxycholate, TUDCA: 
tauroursodeoxycholate, DHCA: dehydrocholate, GCA: glycocholate, TLCA: taurolithocholate , TwMCAs: 
tauro-omega-muricholates, GCDCA: glycochenodeoxycholate, GUDCA: glycoursodeoxycholate. 
Taking together all results of plasma, organ, and fecal bile acid quantification, we can 
conclude, that the spillover of BAs from enterohepatic circulation into plasma does not seem 
to be responsible for the strain difference in the DIO-preventive effect of CA, as it was 
hypothesized in literature before (Watanabe et al., 2006). 
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3.5   Ucp1 is not responsible for the adiposity-preventive effect of cholic acid 
Increased energy expenditure in brown adipose tissue was made responsible for the DIO-
preventive effect of dietary CA-supplementation in published literature (Watanabe et al., 
2006). In a first approach, only indirect proofs were used, e.g. the use of D2 ko mice.  
In order to directly challenge the hypothesis that resistance to diet-induced obesity conferred 
by bile acid supplementation is due to increased thermogenic processes in BAT, we used Ucp1 
ko C57BL/6J mice for a further feeding experiment. Male Ucp1 ko and wildtype BL6J mice, 
respectively, at the age of 6-7 weeks were fed C diet for one week in order to acclimatize to 
the experimental diet. In order to extract the potential CA-derived increase in thermogenic 
processes, we impeded thermogenic processes for body temperature maintenance by 
keeping all animals at thermoneutrality (30 °C). All mice were assigned to one of four diet 
groups: C or H diet, with or without cholic acid (0.5 % w/w) supplementation, respectively. 
Body mass, food intake and body composition were determined in frequent intervals. After 
four weeks of feeding the experimental diet, mice were sacrificed and dissected. Amongst 
others, iBAT, iWAT and eWAT were taken for further analyses. 
3.5.1   No genotype effect on body mass development or body composition  
Seven days before diet change and assignment to one of four experimental diets all mice 
received control diet in order to acclimatize to the texture and composition, which the semi-
purified experimental diets have in comparison to a regular chow diet. During that week, no 
differences in body mass development were observed between diet groups. After assignment 
to one of the four particular diet groups, clear differences occurred already after one week of 
experiment. 
Due to the insertion of one week adaption phase, all BL6J wildtype diet groups absolutely 
gained more weight compared to the mice of the previous experiment.  
At thermoneutrality, H-fed BL6J mice also gained more weight compared to C-fed mice and 
this effect was prevented by CA-supplementation in both wt (p<0.0001) and Ucp1 ko mice 
(p<0.0001), without statistical significant differences due to Ucp1 ko. Sidak’s multiple 
comparisons testing showed that the observed BM restriction significantly affects wt mice 
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from the first week after diet change on. In Ucp1 ko mice this difference becomes significant 
from two weeks after diet change on (Fig. 34). 
 
Fig. 34: Body mass development of wt and Ucp1 ko mice on C or H diet, with or without cholic acid 
supplementation (n=6). Figure modified from Fromme et al. (2019). Body mass development during 
28 days of C and CC (a) or H and HC (b) feeding, respectively. Statistical analysis was conducted for 
each diet group separately. Four separate two-way RM ANOVAs were used with the two factors “time-
point” and “genotype”. In all diet groups, genotype did not affect body mass development. Means with 
standard deviation are shown. 
In contrast to earlier experiments at room temperature, we also observed a significant BM 
gain restriction due to CA-supplementation in C-fed mice at thermoneutrality (taking together 
all C-fed mice of both genotypes): CA-supplementation restricts absolute BM gain of C-fed 
mice (p=0.0025), but no genotype effect was detected. Comparably, in H diet groups CA-
supplementation restricts BM gain of H-fed mice (p=0.0002), as observed in earlier 
experiments at room temperature, but no genotype effect was observed (Fig. 35). 
 
Fig. 35: Total body mass gain after 28 experimental days (n=6). Statistical analysis was conducted for 
C and H diets separately. Two separate two-way ANOVAs were used with the two factors “CA-
supplementation” and “genotype”. No genotype effect was detected. Means with standard deviation 
are shown. 
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Body composition analyses revealed that CA-supplementation significantly reduced fat mass 
accumulation in H-fed mice in both diet groups (p=0.0245 in C, and p=0.0013 in H-fed mice) 
after 28 days of experimental diet feeding. However, no genotype difference was detected. 
Lean mass of H-fed animals significantly differed between both genotypes (p=0.0302), and 
was only affected by CA-supplementation in C-fed animals (p=0.0083). As Ucp1 ko mice 
generally possess less body mass, fat mass and lean mass compared to wt mice, body 
composition parameters were depicted as delta, relating to the start of the experiment (day 
0) (Fig. 36). 
 
Fig. 36: Delta fat mass and delta lean mass (related to baseline values at the start of the experiment 
day 0) of BL6J wt and Ucp1 ko mice after 28 days of experimental feeding (n=6). Figure modified 
from Fromme et al. (2019). Means with standard deviation are shown. 
The observed differences in body weight and fat mass conferred by cholic acid 
supplementation cannot be attributed to differences in food intake, as absolute food intake 
at week four did not differ, neither between diet groups nor between genotypes (Fig. 37).  
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Fig. 37: Cumulative food intake of C57BL/6J wt and Ucp1 ko mice during four weeks of C and CC (a) 
or H and HC (b) diet feeding, respectively (n=6). 
3.5.2   Brown and white adipose tissue weight analyses 
Cholic acid supplementation did not affect iBAT mass of neither wt nor Ucp1 ko BL6J mice. It 
tended towards reducing iBAT mass of H-fed wt and ko mice, however statistically not 
significant. iBAT activity or function is not predicated on iBAT mass. Probably, the slight 
reduction of iBAT mass in H-fed animals, as it was also seen in earlier experiments, is only a 
cause of cholic acid induced body fat reduction, whereupon embedded white adipocytes 
within iBAT are reduced in size (Fig. 38). 
 
Fig. 38: iBAT mass after 28 experimental days (n=6). Means with standard deviation are shown. 
Statistical significance was tested using two separate two-way ANOVA analyses, each for C and H diets, 
respectively, with the two factors “CA-supplementation” and “genotype”. None of the two factors 
influenced iBAT mass. 
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Epididymal and inguinal WAT masses were analyzed both separately and pooled. Congruent 
with former experiments (and body mass/ other results obtained in this trial) the H feeding 
induced increase of WAT weight is abrogated by cholic acid supplementation in wt, but also 
in ko mice. To analyze the influence of the two factors “CA-supplementation” and “genotype” 
on eWAT and iWAT masses, we used two separate two-way ANOVAs for each C and H diets. 
In C diets, CA-supplementation was found to significantly influence pooled WAT mass 
(p=0.0062), whereas genotype does not. In H diets, both CA-supplementation (p=0.0023) as 
well as genotype (p=0.0085) significantly influenced pooled WAT mass, but no interaction 
between both factors was detected (Fig. 39). These observances point towards generally 
reduced WAT mass increase due to H feeding in Ucp1 ko mice, as well as a reduction of WAT 
mass in both genotypes due to CA-supplementation. However, CA-driven prevention of 
pooled WAT accumulation due to H feeding is equally potent in both genotypes. 
 
Fig. 39: Pooled WAT (both iWAT and eWAT) mass in wt and ko mice after 28 experimental days (n=6). 
Means with standard deviation are shown. Statistical significance was tested using two separate two-
way ANOVA analyses, each for C and H diets, respectively, with the factors “CA-supplementation” and 
“genotype”. 
Similar results were obtained, if iWAT and eWAT data were analyzed separately: 
CA-supplementation significantly reduced iWAT mass of C-fed mice (p=0.0261) and of H-fed 
mice (p=0.0042) in both genotypes. Moreover, iWAT mass significantly differed between both 
genotypes (p=0.0334). There was no interaction between both factors in none of the two 
different diet groups (Fig. 40a). eWAT mass of C-fed mice was significantly influenced by both 
factors genotype (p=0.0105) and CA-supplementation (p=0.0029). The same result was 
obtained for eWAT mass of H-fed mice, as it was significantly reduced by CA-supplementation 
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(p=0.0016) and Ucp1 ko (p=0.0028). There was no interaction between both factors in none 
of the two different diet groups (Fig. 40b). 
 
Fig. 40: Separate analyses of iWAT and eWAT mass in wt and ko mice after 28 experimental days 
(n=6). Means with standard deviation are shown. Statistical significance was analyzed for iWAT and 
eWAT separately. For each iWAT and eWAT, there were used two separate two-way ANOVA analyses, 
for C and H diets, respectively, with the two factors “CA-supplementation” and “genotype”. 
3.5.3   Blood parameter analysis 
Piccolo Lipid Panel Plus Reagent Discs (Abaxis, Inc.) were used for the in vitro quantitative 
determination of total cholesterol, high-density lipoprotein cholesterol (HDL), triglycerides, as 
well as glucose, respectively, in heparinized plasma samples. Moreover, we determined 
plasma levels of the liver enzymes alanine aminotransferase (ALAT) and aspartate 
aminotransferase (ASAT), which are biomarkers for liver health. 
We targeted on revising beneficial effects of dietary CA-supplementation, which is supposed 
to partially revert the pathological impact of H diet, and to generally compare plasma 
parameters of BL6J wt to Ucp1 ko mice. 
As described in literature, the collected data patterns a general trend towards improving the 
H diet caused negative impact on blood parameters. The H diet-caused increase of cholesterol 
(p=0.0033), glucose (p=0.0014) and HDL (p=0.0132) levels was reduced by CA-
supplementation. There was also seen a certain reduction of the respective plasma levels of 
C-fed animals. This trend was significant for cholesterol and HDL. We also observed a 
statistically significant genotype difference for cholesterol of C-fed animals (p=0.0260). In 
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summary, CA-supplementation partially causes improvement of blood parameters in H-fed 
mice (Fig. 41). 
 
Fig. 41: Plasma parameter analysis in BL6J Ucp1 ko and wt mice, separated for diets (n=6). Plasma 
cholesterol (a), HDL (b), triglycerides (c), and glucose (d), means with standard deviation are shown. 
Two separate two-way ANOVAs were conducted for C and H diets, factors “CA-supplementation” and 
“genotype”. 
In contrast to these rather beneficial impacts, we also observed pathological side effects of 
CA-supplementation, as liver enzyme levels were increased in both CA-supplemented diets. 
Especially in H-fed animals, mean ALAT levels were increased 10-fold in wt and 8-fold, and 
ASAT levels were increased 6-fold in wt and 4-fold in ko mice due to CA-supplementation (Fig. 
42). These increases were especially pronounced in single animals, resulting in high standard 
deviations. Therefore, the observed increase was only significant for ALAT of H-fed animals 
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(p=0.0179, two-way ANOVA over both wt and ko mice on H diet, factors “CA-
supplementation” and “genotype”). If both genotypes are analyzed separately, the CA-
supplementation-caused increase of ASAT and ALAT in H-fed ko mice is statistically significant 
(ALAT: p=0.0046, and ASAT: p=0.0186; unpaired t-tests). 
C and CC-fed Ucp1 ko mice generally seemed to obtain higher ALAT and ASAT levels compared 
to H-fed animals as well as compared to wt mice. However, these observances only are 
significant for ALAT levels of C-fed animals. 
 
Fig. 42: Liver enzyme analysis in BL6J Ucp1 ko and wt mice, separated for diets (n=6). ASAT (a) and 
ALAT (b), means with standard deviation are shown. Two separate two-way ANOVAs were conducted 
for C and H diets, factors “CA-supplementation” and “genotype”. 
Summarizing all results from the plasma metabolic marker analysis, we observed a CA-
supplementation induced trend towards improvement of H diet caused impairment of 
selected plasma parameters. However, this improvement goes hand in hand with 
pathologically elevated liver enzyme levels (ASAT and ALAT), which points towards an 
impairment of liver functionality in both genotypes. 
Taking together all results obtained from Ucp1 ko mouse studies, the Ucp1 gene knockout did 
not lead to a loss of the DIO-preventive effect of CA-supplementation in this experiment, as 
Ucp1 ko mice in all diet groups showed BM developments as well as body compositions, that 
are comparable to those of wt mice. These results stand in clear contrast to published 
literature. In conclusion, the DIO-preventive effect of dietary cholic acid supplementation 
must be independent of the Ucp1 gene. 
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4    DISCUSSION 
During the last years, a new role for circulating bile acids has emerged, as bile acids do not 
only solubilize dietary lipids, cholesterol or fat-soluble vitamins, but also function as signaling 
molecules and thereby mediate various metabolic effects. Bile acids activate nuclear receptors 
like FXR (Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999), the G-protein coupled 
receptor TGR5 (Kawamata et al., 2003; Maruyama et al., 2002) and cell signaling pathways in 
hepatocytes or enterocytes (Dent et al., 2005; Fang et al., 2007). Thereby bile acids influence 
e.g. glucose or fatty acid metabolism and contribute to the prevention or amelioration of 
characteristic features of the metabolic syndrome, as they e.g. protect mice against hepatic 
lipid accumulation, increased plasma triacyl glycerol and glucose levels (Liaset et al., 2011) and 
can prevent as well as reverse diet-induced obesity (Watanabe et al., 2006). The inverse 
correlation between systemic bile acid levels and body fat mass was not only observed in mice, 
but also was proved in men (Suzuki et al., 2014).  
In order to increase the understanding how BAs mediate body mass stabilization, we 
investigated BA derived effects on two different inbred mouse strains, with a special focus on 
the generation of brite adipocytes in iWAT as well as energy expenditure analyses. 
Furthermore, we used Ucp1 knockout mice to clarify the participation of non-shivering 
thermogenesis at this effect.  
4.1   Cholic acid derived prevention from diet-induced obesity in C57BL/6J 
mice 
In our study we were able to reproduce the DIO-protective effect of cholic acid (CA) in BL6J 
mice, that has been described previously (Teodoro et al., 2014; Watanabe et al., 2011; 
Watanabe et al., 2006; Watanabe et al., 2012; Zietak and Kozak, 2016), as HC-fed mice showed 
a significantly lower body mass increase compared to H-fed mice without differences in energy 
intake. Body mass stabilization in HC-fed BL6J mice could be fully explained by a significant fat 
mass reduction due to CA-supplementation, whereas lean mass was not affected. Intriguingly, 
body mass was not further reduced in CC-fed animals compared to C-fed mice. This 
phenomenon is already confirmed on cell level by in vitro experiments, where isolated BAT 
cells were treated with TCA and cells from H-fed mice were more sensitive to the addition of 
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TCA than cells from chow fed mice (Watanabe et al., 2006). Yet it needs to be clarified why 
this effect is only present in relation to high-fat diets.  
As CA-supplementation did not affect energy assimilation, we hypothezised, that energy 
expenditure was the site to analyze BA effects on body mass stabilization. Due to a spillover 
from liver into blood circulation, BAs reach peripheral sites of action. Thus it was hypothesized, 
that BAs bind TGR5 in BAT and initiate a signaling cascade, where cAMP-dependent thyroid 
hormone activating enzyme type 2 iodothyronine deiodinase (D2) is induced. Thereby D2 
converts inactive thyroxine (T4) into the active 3,5,3’-tri-iodothyronine (T3) (Bianco et al., 
2002). Besides, other key genes in energy expenditure were reported to be increasingly 
expressed in BAT after BA feeding, amongst others PGC-1α, which is the main regulator of 
mitochondrial biogenesis (Weitzel et al., 2003), and UCP1, which mediates non-shivering 
thermogenesis in BAT. Thereby energy expenditure in BAT and skeletal muscle shall activated, 
leading to adiposity prevention and insulin sensitization(Watanabe et al., 2006). In BAT, this 
mechanism is proposed to be driven by an enhanced Ucp1 mRNA expression (Watanabe et 
al., 2006).  
In order to assess the influence of BA-supplementation on BAT, we investigated iBAT mass 
and morphology as well as Ucp1 mRNA expression levels of BL6J mice, which were fed either 
a low fat control diet (C) or a high-fat diet (H) non-supplemented or supplemented with cholic 
acid (CC and HC). Comparable to previously published results, iBAT of HC-fed mice weighed 
significantly less than iBAT of their H-fed counterparts. Microscopic analyses confirmed that 
not only surrounding WAT mass, but also lipid content of brown adipocytes was reduced due 
to CA-supplementation. This effect could not be observed in iBAT of CA-supplemented C-fed 
mice. Besides reduction of adipocyte hypertrophy, it has already been shown by electron 
microscopic analyses, that CA-supplementation leads to an increase in the number of lamellar 
cristae in iBAT mitochondria. This effect goes along with an increase of iBAT Ucp1 mRNA 
expression (Watanabe et al., 2006). Moreover, it was shown, that also CDCA-supplementation 
to H diet increases iBAT Ucp1 mRNA expression as well as UCP1 protein content in C57BL/6J 
mice (Teodoro et al., 2014). In contrast to that, we were not able to confirm this effect, as we 
observed a significant reduction of iBAT Ucp1 mRNA expression levels in HC-fed mice. In order 
to approve and further explain our result, iBAT UCP1 measurements on protein level need to 
be performed. However, HC-feeding showed to significantly reduce iWAT mass as well as 
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adipocyte lipid content in BL6J mice. Microscopic analyses revealed the occurrence of 
multilocular cells in iWAT of HC-fed BL6J mice. With respect to browning, we used qPCR 
measurements to confirm the induction of the BAT-selective genes Ucp1, Cox7A1, CideA and 
Otop1. We found an overall increase of BAT-selective gene expression in iWAT due to CA-
supplementation to H diet, as well as a moderate, but significant increase of Ucp1 transcript 
abundance as reported earlier (Teodoro et al., 2014; Zietak and Kozak, 2016), an effect 
probably caused by direct interaction of bile acids with TGR5 (Velazquez-Villegas et al., 2018). 
Moreover, immunohistochemical staining for UCP1-positive cells in iWAT showed a relative 
browning effect of CA-supplementation in H-fed BL6J mice. The bile acid-derived promotion 
of fat oxidation was not only proved after dietary bile acid supplementation, but also after 
continuous intracerebroventricular bile acid infusion, (Eggink et al., 2017), showing that bile 
acids may exert metabolic effects on fat metabolism via the brain. Besides, supplementing a 
gut-restricted agonist for the bile acid sensor farnesoid X receptor (FXR) induces enteric 
fibroblast growth factor 15 (FGF15) and thereby alters BA composition, reduces DIO, enhances 
thermogenesis and WAT browning (Fang et al., 2015). Therefore, the influence of BAs on 
metabolism seems to have different sites of action, as cerebral as well as peripheral-mediated 
BA signals lead to similar effects like DIO-resistance or WAT browning. 
We can confirm that CA-supplementation effectively prevents BL6J mice from DIO by 
significantly decreasing WAT mass. Moreover, CA-supplementation significantly increases 
brown fat marker expression and leads to a recruitment of UCP1-positive multilocular cells in 
iWAT of H-fed BL6J mice, but has none of these effects in C-fed BL6J mice. 
4.2   Cholic acid supplementation does not induce energy expenditure in 
C57BL/6J mice 
We hypothesized, that energy expenditure must be responsible for the DIO-preventive effect 
of CA-supplementation, as it neither affected food nor energy intake. In order to analyze the 
influence of CA-supplementation on energy expenditure, indirect calorimetry as well as 
feeding-drinking-activity measurements were performed on C57BL/6J mice. Already one day 
after diet change, clear differences between H and HC-fed animals were observed. Mean RER 
of both diet groups was lowered. All mice displayed the typical circadian rhythm of nocturnal 
activity accompanied by high heat production and preferred carbohydrate usage as compared 
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to lower heat production and preferred lipid use during daytime. However, CA-
supplementation stimulated an accentuation of the H-diet-induced decrease of RER, which 
verifies that BA-supplementation increases fat oxidation, as already described in earlier 
publications (Teodoro et al., 2014; Watanabe et al., 2006). Furthermore, we observed a time-
delayed shift of mean RER pattern in HC-fed mice, which has not been shown or discussed 
before. This shift suggests that HC-fed mice either start feeding at later time points compared 
to H-fed mice, probably due to an unpleasant flavor of CA, which is known to exhibit a bitter 
taste, or that CA-supplementation leads to an altered metabolism, where lipid metabolism 
phase is prolonged and the change to carbohydrate metabolization is delayed. 
Despite body mass and body composition developments that were comparable to the results 
of our former experiments, as well as the observed differences in mean RER, daily energy 
expenditure as well as resting metabolic rate did not differ between H and HC-fed mice after 
body mass adjustment. Thus, mice displayed a DEE appropriate for their individual body mass 
regardless of dietary bile acid supplementation at all times and only differences in body mass 
accounted for the differences in energy expenditure. Nevertheless, our data can not be 
resolved high enough to explain the minor differences in energy balance, that accumulate to 
the final differences in body weight and composition. Food intake measurements potentially 
were not accurate enough to reveal the relevant changes in energy intake that might account 
for the observed phenomenon. Previous studies stated that BA-mediated prevention of DIO 
could not be traced back by a decreased food intake. However, food intake oftentimes was 
adjusted to the animals’ BW (Watanabe et al., 2011; Watanabe et al., 2006; Watanabe et al., 
2012). Thereby a decrease in absolute food intake could be disguised with a decreased BW, 
which occurred after CA-supplementation. In studies, where a food intake per mouse was 
considered, a transient decrease in food intake could be observed at the beginning of the 
intervention (Teodoro et al., 2014). During these studies, pair-feeding experiments were 
conducted in order to dissect the effect of BA-supplementation on body mass per se. Pair-
feeding revealed that the DIO-preventive effect of BAs mostly traces back to a reduced food 
intake. However, a relatively mild and food intake-independent reduction in adiposity (not 
detectable on body weight level) could be observed, as well (Teodoro et al., 2014). 
Our data cannot support the hypothesis that dietary bile acid supplementation increases 
energy expenditure as described before (Ockenga et al., 2012; Watanabe et al., 2006; Zietak 
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and Kozak, 2016). However, none of these observations doubtlessly proved that bile acid 
supplementation to mice causes an increase in energy expenditure. Data of Watanabe et al., 
2006 is only based on a 15 hours indirect calorimetry measurement and normalized to body 
mass (Watanabe et al., 2006), a procedure not advisable in animals of different body mass and 
composition (Butler and Kozak, 2010; Tschop et al., 2011). Ockenga et al., 2012 did not show 
original data on O2-consumption or VO2-production, but only presented calculated values of 
energy expenditure, whose basis of calculation is not explained within this article (Ockenga et 
al., 2012). Zietak and Kozak, 2016 only consulted an indirect prove by estimating total energy 
expenditure with the help of a formula, that basically subtracts change in body energy stores 
from caloric intake (Ravussin et al., 2013; Zietak and Kozak, 2016). Moreover, two 
independent studies by other laboratories measuring the impact of dietary bile acid 
supplementation found no effect on energy expenditure (da-Silva et al., 2011; Teodoro et al., 
2014). 
To sum up, we cannot confirm an increase in energy expenditure in response to cholate 
supplementation, neither in absolute terms nor adjusted and neither at rest nor as a daily 
budget. As this conclusion was also drawn in other laboratories (da-Silva et al., 2011; Teodoro 
et al., 2014), we conclude that the contribution of brown fat thermogenesis to DIO-resistance 
conferred by cholate supplementation is questionable. 
4.3   Cholic acid derived prevention from diet-induced obesity is strain 
specific 
As bile acid derived prevention of DIO is claimed to result from increased BAT activity, we 
speculated that brite adipocyte recruitment may have an important influence and additionally 
contributes to the body mass stabilizing outcome. We used 129S6 mice to study the browning 
potential observed in BL6J mice by CA supplementation and eventually to potentiate it within 
this strain, as 129S6 mice have a higher propensity to recruit brite adipocytes. The 129S6 mice 
received the same diets and experimental treatments as the BL6J mice. 
In contrast to our hypothesis, 129S6 mice were not at all responsive for CA-supplementation, 
as no differences emerged between non-supplemented and supplemented diet groups. All 
metabolic consequences of the CA-supplementation observed in C57BL/6J animals are 
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completely absent in 129S6 mice: Neither body mass development, nor iBAT or iWAT mass, 
morphology and gene expression profile was influenced by CA-supplementation. These results 
clearly exhibit the novel finding, that the prevention of DIO by BAs is mouse strain specific. 
With the help of this phenomenon, we obtained the possibility to specifically study strain 
specificities and thereby elucidate the adiposity protective effects of BAs in BL6J mice.  
We started to compare both mouse strains by the enteral bile acid transporters ASBT and OST. 
ASBT is located at the apical membrane of ileal enterocytes and responsible for the uptake of 
bile acids from gut lumen across the apical brush border membrane of the enterocyte 
(Shneider, 2001). An Asbt knockout results in a down-regulation of FXR target genes such as 
Fgf15. The decreased Fgf15 expression as well as the reduced return of BAs to the liver results 
in an increased Cyp7a1 expression, thus resulting in an increased translation of the rate-
limiting enzyme in the classical BA synthesis pathway. Accordingly, BA synthesis is increased 
by the Asbt gene knockout (Dawson, 2015). The heteromeric BA transporter OSTα-OSTβ is 
located at the enterocyte’s basolateral membrane. Ostα and Ostβ actually are expressed in 
most tissues, but are most abundant in tissues involved in bile acid and steroid homeostasis 
(Ballatori et al., 2009). In Ostα knockout mice, Fgf15 expression is increased due to an 
increased BA storage in the enterocyte. Thereby Cyp7a1 gene expression is decreased and BA 
synthesis limited (Dawson, 2015; Rao et al., 2008). We were in fact able to identify strain 
specific differences, which might be jointly responsible for the varying bile acid absorption. 
For this reason, and as we could not observe a difference in food intake and thereby CA uptake 
between both strains, we suspected differences in CA uptake within gut and spillover into 
circulation or in CA excretion. Therefore, BA analyses were conducted to determine BA 
concentration and composition in plasma, enterohepatic organs and feces. 
Plasma BA analysis revealed that BL6J mice generally exhibit higher plasma BA levels 
compared to 129S6. Plasma BA levels were found to be influenced by both CA-
supplementation and strain, respectively, in H diet groups. Additionally, we confirmed a higher 
plasma BA-raising effect for supplemented H-fed BL6J compared to 129S6 animals. There were 
not found major differences in plasma BA composition between strains or diet groups.  
Organ bile acid pool was significantly influenced by strain and CA-supplementation: BL6J mice 
naturally possess a higher organ BA pool size compared to 129S6 mice, and CA-
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supplementation led to a significant increase in organ pool size in both strains. Thereby, organ 
BA pool was stronger raised in BL6J compared to 129S6 animals. Compositional differences 
were merely seen due to CA-supplementation and not due to strain. 
Fecal BA excretion mass also was increased due to CA-supplementation in both strains and 
diets. A strain effect as well as a diet-strain interaction was observed in C-fed animals, with a 
stronger increase of BA excretion in CA-supplemented BL6J mice compared to 129S6 mice. 
Similar to the other compartments, no differences were observed in fecal BA composition. 
Taking together all results we can conclude that the spillover of BAs from enterohepatic 
circulation into plasma might account for the BA-derived effects itself, but does not seem to 
be responsible for the strain difference. As the relevant strain specific differences of H-fed 
animals were already seen in organ BA concentrations, and strain-specific differences in 
plasma BA levels only reflect those in enterohepatic organs, the CA-derived prevention of DIO 
must originate from a site of action, which is located downstream of plasma circulation. 
Differences in plasma BA levels might be responsible for the CA-derived DIO-preventive effect 
in H diets only. As no effect of neither strain nor CA-supplementation was found in plasma BA 
levels in C-fed animals, but plasma BA levels were stronger increased in CA-supplemented H-
fed BL6J mice, the relevant site of action might be along plasma circulation. 
4.4   Using C57BL/6J Ucp1 knockout mice to challenge the hypothesis of 
UCP1-derived prevention of diet-induced obesity by cholic acid 
In the absence of increased energy expenditure, the contribution of brown fat thermogenesis 
to DIO resistance conferred by CA-supplementation is questionable. We nevertheless 
conducted the appropriate experiment to investigate this possibility by including Ucp1 ko mice 
into a feeding trial, according to the initial experiments with BL6J and 129S6 mice.  
In general, iBAT Ucp1 expression is decreased under thermoneutral conditions (Freeman et 
al., 1989; Rippe et al., 2000), as UCP1 is not needed to maintain body temperature. Moreover, 
Ucp1 ko mice were described to be DIO-resistant at room temperature (20° C), as they have 
to maintain normal body temperature without non-shivering thermogenesis, but by using less 
efficient, more energy consumptive pathways of metabolism (Liu et al., 2003). It has been 
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described that only UCP1 can mediate adaptive non-shivering thermogenesis in the cold and 
Ucp1-deficient mice shiver to maintain their body temperature (Golozoubova et al., 2001; 
Nedergaard et al., 2001). For this reason, and in order to subtract the energy expenditure used 
for body temperature maintenance as well as to distinctly quantify the BA-derived increase of 
energy expenditure, the experiment was conducted at thermoneutrality.  
At room temperature, mice approximately use one third of the consumed calories to maintain 
body temperature (James and Trayhurn, 1981). Under thermoneutral conditions, no energy 
has to be expended to maintain body temperature. Accordingly, if food intake is not limited, 
excess energy from a high-fat diet is stored in adipose tissue and animals show an increased 
body mass gain compared to keeping at room temperature (Cui et al., 2016; Stemmer et al., 
2015). In contrast, low-fat diet fed animals are able to regulate their appetite, resulting in a 
maintained body weight balance (Enerback et al., 1997). Under high-fat diet, however, it has 
already been described that food intake is not reduced, resulting in an increased body weight 
of high-fat diet fed animals at thermoneutrality (Rippe et al., 2000). During our thermoneutral 
experiment, the animals indeed reduced their food intake compared to the experiments at 
room temperature, but this reduction was not great enough to compensate for the decreased 
need of energy intake. 
As described before, we used Ucp1 ko mice to investigate its necessity to mediating BA-
derived DIO-resistance and thereby clearly demonstrate that UCP1-dependent, non-shivering 
thermogenesis in brown or brite adipocytes is not required for bile acid mediated protection 
against DIO. This conclusion, however, is in disagreement with the results of a very similar 
experiment with the same mouse strain conducted unknowingly in parallel in L. Kozak’s 
laboratory (Zietak and Kozak, 2016). Here, Ucp1 ko mice were not protected against DIO by 
CA-supplementation. However, even the role of UCP1 itself in the development of DIO is not 
fully resolved. In different studies, the identical Ucp1 ko mouse strain is more (Feldmann et 
al., 2009; Rowland et al., 2016; von Essen et al., 2017), less (Liu et al., 2003) or similarly prone 
to DIO (this study, Maurer, 2016; Winn et al., 2017; Zietak and Kozak, 2016), even from cohort 
to cohort within the same colony (Von Essen, 2017).  
For example, the studies of Liu et al. revealed that Ucp1-deficient mice are DIO-resistant at 
room temperature. Control wildtype mice significantly gained more body mass on a high-fat 
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diet. This difference, however, was reverted if ambient temperature was raised to 27 °C. 
Moreover, Ucp1 ko mice generally possessed lower RER values and it was shown, that this 
effect is not dependent on the ambient temperature, but on the diet’s fat content. Moreover, 
Ucp1 ko mice apparently had a basic difference in substrate utilization compared to wt mice. 
From all their findings, Liu et al. hypothesized, that thermogenesis in Ucp1 ko mice is 
metabolically more expensive and for these reasons Ucp1 kos paradoxically are protected 
against obesity (Liu et al., 2003). Nevertheless, investigations failed to demonstrate an obese 
phenotype in Ucp1 ablated mice (Enerback et al., 1997; Liu et al., 2003).  
In contrast to that, Feldmann and colleagues showed that an Ucp1 ablation in itself is sufficient 
to induce obesity under thermoneutral conditions (Feldmann et al., 2009). In their 
experiments, body fat depots’ weights were significantly increased in both low fat and high-
fat diet fed mutant mice, respectively. In conformity with Liu et al., they speculated that under 
thermoneutral conditions, there is no longer a need for a chronically elevated metabolism, as 
it is normally required at room temperature to maintain body temperature. Room 
temperature actually is a chronic thermal stress for mice, as they have to defend their body 
temperature at a low grade constantly. This is ensured by an increased food intake (Feldmann 
et al., 2009). 
In our hands, no difference in neither body weight, fat nor lean mass development was 
detected between wildtype and Ucp1 ko BL6J mice under thermoneutral conditions. Both 
genotypes accumulated excess adipose tissue due to H-feeding. Comparable to experiments 
on wt BL6J mice at room temperature, CA-supplementation also leads to DIO-resistance and 
reduced accumulation of WAT depots in both BL6J wt and Ucp1 ko mice at thermoneutrality. 
Compared to room temperature, BL6J wt mice absolutely gained more body mass under 
thermoneutral conditions, as shown in earlier experiments (Rippe et al., 2000), but were also 
prevented from DIO, independently of their genotype. For this reason, we conclude, that the 
DIO-protective effect of CA-supplementation is independent of Ucp1. 
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4.5   Relevance in humans 
To this day it has not been investigated whether cholic acid also exerts all of these positive 
effects on metabolic outcomes in men. If the findings obtained in rodent studies relating to 
weight control or glucose and lipid metabolism can be confirmed in human studies, such drugs 
would be highly attractive (Jenkins et al., 2008). 
It has been proposed, that the DIO-preventive effect exerted by CA-supplementation might 
also be present in men, as the treatment of brown adipocytes and human skeletal myocytes 
with BA were shown to increase D2 activity and oxygen consumption via the activation of 
UCP1. It was postulated, that this effect is also mediated by TGR5-activation (Watanabe et al., 
2006). However, the mere co-expression of the ubiquitously expressed BA receptor TGR5 and 
D2 in human skeletal muscle cells does not necessarily implicate a direct link of BA-D2-Ucp1 
pathway in human BAT. 
Since metabolically active brown adipose tissue has been identified in adult humans (Cypess 
et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen et al., 2009) brown adipose tissue 
activity has become an interesting target for the treatment of obesity, especially as the 
amount and activity of BAT in men is inversely correlated with body-mass index (Cypess et al., 
2009) and percentage of body fat, but positively correlated with resting metabolic rate (van 
Marken Lichtenbelt et al., 2009). In addition, BAT-positive subjects are of comparatively 
younger age, have lower fasting insulin levels and insulin resistance, but a greater level of high-
density lipoprotein cholesterol than individuals without BAT (Zhang et al., 2013). 
In a study supplementing the primary bile acid chenodeoxycholic acid (CDCA) and investigating 
BAT activity via PET/CT examinations, it was shown that CDCA-supplementation indeed 
increases human BAT activity. However, the authors could not exclude, that BAs increase 
energy expenditure via BAT-independent mechanisms (Broeders et al., 2015). Nevertheless, 
as CDCA showed to be BAT-activating in humans, the other primary bile acid CA might be a 
promising BAT-activator, as well. 
Humans have long been treated with the tertiary bile acid ursodeoxycholic acid (UDCA), which 
is formed in the liver by epimerization of the secondary bile acid lithocholic acid and naturally 
occurring in high concentration in the bile of the Chinese black bear (Gray). UDCA improves 
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fat digestion and absorption in cystic fibrosis patients with mild liver involvement (Drzymala-
Czyz et al., 2016). Moreover, UDCA is used in the therapy on gallstone formation (Worobetz 
et al., 1993), or chronic liver disease (Guslandi, 1990) and has shown chemopreventive 
potential in colon cancer (Solimando et al., 2011). However, the respective studies have not 
focused on whether the often accompanying weight loss was more pronounced in the UDCA-
treated group, or whether UDCA drugs used to prevent gallstone formation had an effect 
beyond that of bariatric surgery itself (Worobetz et al., 1993).  
After Roux-en-Y gastric bypass (RYGB) surgery, in which the stomach’s small upper pouch is 
directly connected to the small intestine (Andalib et al., 2015), total fasting BAs are increased 
compared to preoperative levels. This effect was not observed after purely restrictive 
procedures like adjustable gastric banding (Kohli et al., 2013; Patti et al., 2009; Pournaras et 
al., 2012). RYGB is the most effective treatment for morbid obesity and diabetes (Kashyap et 
al., 2013; Schauer et al., 2012). However, the resolution of diabetes and other comorbid 
conditions typically occurs before significant weight loss. As bile acid homeostasis is a tightly 
regulated process, and bile acid level and composition are rapidly adapted after RYGB, BAs 
have been identified as one class of putative compounds involved in the weight-independent 
effects of bariatric surgery. Overall findings on bile acid changes after bariatric surgery 
propose that especially bacterially derived, secondary BAs may mediate the early 
improvements after RYGB (Albaugh et al., 2015; Lutz and Bueter, 2014). These observations 
suggest an important influence of not only BA concentration, but also composition on 
metabolic outcomes. Moreover, an inverse correlation between postprandial bile acid 
concentration and body fat mass in healthy normal-weight subjects has been proven (Suzuki 
et al., 2014). The underlying mechanisms, however, have not been elucidated, yet. 
Besides their positive metabolic impacts, bile acids may also exert deleterious effects if 
supplemented. As bile acids are potent detergents and cytotoxic at higher concentrations, 
their synthesis is normally tightly controlled and bile acid concentration normally maintains 
within narrow limits, to avoid cellular injury. Bile acids themselves are known to be cytotoxic 
to hepatocytes (Malhi et al., 2010) and early human studies confirm bile acid toxicity in 
primary human hepatocytes e.g. using GCDCA (Galle et al., 1990). Therefore, increased bile 
acid concentrations that for example are caused by bile acid supplementation can also 
generate a series of problems: Bile acids can induce arrhythmias (Desai and Penny, 2013), not 
DISCUSSION   89 
 
 
 
 
only in adults but also in fetuses. Intrahepatic cholestasis of pregnancy, where bile acid 
concentrations are pathologically raised in the mothers circulation, causes fetal arrhythmia 
and sudden intrauterine death (Sheikh Abdul Kadir et al., 2010). Besides, dietary lithocholic 
acid supplementation was shown to result in intrahepatic cholestasis and bile infarcts. This 
hepatotoxic effects went in line with a significant increase in plasma ALAT levels (Woolbright 
et al., 2014), an effect that we also observed in response to dietary cholic acid 
supplementation in BL6J mice. For this reason, the currently known positive effects of a 
dietary bile acid supplementation are not great enough to legitimate the negative 
consequences accompanying a bile acid treatment in humans. 
4.6   Conclusion and perspective 
In summary, we here report that the DIO-protective effect of a dietary cholic acid 
supplementation is mouse strain specific, does not increase energy expenditure and does not 
require UCP1-dependent, non-shivering thermogenesis. 
The black and white strain difference observed in the metabolic response of C57BL/6J and 
129S6/SvEvTac mice certainly proves a valuable model to elucidate molecular mechanistic 
determinants of these processes. However, it remains to be clarified which of the two strains 
is more representative for other mouse strains, other commonly used animal models and 
humans. Disconcertingly, a large body of literature on effects of dietary cholate 
supplementation relies on experiments with the C57BL/6J mouse strain (da-Silva et al., 2011; 
Teodoro et al., 2014; Watanabe et al., 2011; Watanabe et al., 2006; Watanabe et al., 2012; 
Zietak and Kozak, 2016). Past conclusions will have to be reviewed in the light of the very 
specific genetic background leading to exceptionally high bile acid sequestration and spillover 
in this strain and the new finding that all of these effects may be strain-specific. 
Furthermore, dietary cholic acid supplementation also seems to recruit brite adipocytes in 
C57BL/6J iWAT. However, its underlying thermogenic capacity is not great enough to explain 
the prevention of adipose tissue accumulation during H diet. Moreover, indirect calorimetry 
measurements did not hint at an increased energy expenditure mediated by the CA-
supplementation. We were not able to detect differences in energy intake, energy 
expenditure or energy loss with feces, respectively. Nevertheless, substantial body weight 
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differences were observed between CA-supplemented and non-supplemented H-fed BL6J 
animals. Our analytical apparatuses either were not sensitive enough to explain the minor 
differences in energy balance that in the end account for the DIO-protection of CA-
supplementation, or more likely, CA-supplemented H-fed animals consume less food 
compared to non-supplemented mice. This would not explain why CA-supplemented C-fed 
animals do not loose further weight compared to non-supplemented C-fed mice, yet. 
In the end, we clearly showed that the DIO-preventive effect of bile acids is independent of 
UCP1, as the respective knockout animals are protected in the same manner as wildtype 
animals. This is in line with the results obtained from indirect calorimetry measurements that 
also did not provide a basis for an increased non-shivering energy expenditure mediated by 
UCP1. 
Data on the effects of bile acids is diversely discussed in literature. The underlying mechanisms 
of bile acid-derived effects on energy expenditure still are not doubtlessly elucidated. Bile 
acids in general display a wide range of steroid compounds that are not well studied up to 
date, but might be promising metabolic active effectors.  
Despite all the positive impacts that are described in literature and assigned to bile acids, we 
must not forget that bile acids are potent detergents and cytotoxic at higher concentrations. 
Under physiologic conditions, bile acid synthesis is tightly controlled and BA concentration 
normally maintains within narrow limits to avoid cellular injury (in healthy objects, without 
BA-supplementation). A bile acid supplementation that e.g. prevents from diet-induced 
obesity also elevates systemic bile acid concentrations to cytotoxic levels. Therefore, the 
currently known positive effects of a dietary bile acid supplementation are not great enough 
to legitimate the negative consequences accompanying a bile acid treatment in human. In the 
future, any advantages and disadvantages of bile acid supplementation must be carefully 
considered. 
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APPENDIX 
Table 10: External and internal standards used for bile acid quantification by means of UPLC/TOF-MS. 
 Abbreviation Molecular mass 
[M-H]-  
Company  Order number  
Chenodeoxycholic acid  CDCA 391.285383  Sigma C9377 
Cholic acid  CA  407.280298  Sigma  C1129 
Deoxycholic acid  DCA  391.285383  Sigma  D2510  
Glycochenodeoxycholate, sodium  GCDCA  448.306847  Sigma  G0759 
Glycocholic acid, hydrate  GCA  464.301762  Sigma  G2878 
Glycodeoxycholic acid, sodium  GDCA  448.306847  Calbiochem  361311 
Glycoursodeoxycholic acid  GUDCA  448.306847  Sigma  06863  
Dehydrocholic acid  Dehydro-CA  391.285383  Sigma  30830 
Lithocholic acid  LCA  375.290469  Sigma  L6250  
Taurochenodeoxycholate, sodium  TCDCA  498.289483  Sigma  T6260 
Taurocholic acid, sodium hydrate  TCA  514.284397  Sigma  T4009 
Taurodeoxycholate, sodium hydrate  TDCA  498.289483  Sigma  T0875 
Taurolithocholate, sodium  TLCA  482.294568  Sigma  T7515 
Tauroursodeoxycholic acid, sodium  TUDCA  498.289483  Calbiochem  580549 
Ursodeoxycholic acid  UDCA  391.285383  Sigma  U5127 
α-Muricholic acid  αMCA  407.280298  Steraloids  C1890-000  
α-Tauromuricholic acid  αTMCA  514.284397  Steraloids  C1893-000  
β-Muricholic acid  βMCA  407.280298  Steraloids  C1898-000  
β-Tauromuricholic acid  βTMCA  514.284397  Steraloids  C1899-000  
ω-Muricholic acid  ωMCA  407.280298  Steraloids  C1888-000  
d4-Cholic acid  d4-DCA  411.304308  Sigma  D-2452  
d4-Deoxycholic acid  d4-DCA  395.309393  CDN Isotopes  D-2941  
d5-Taurocholic acid  d5-TCA  519.314684  Toronto research chemicals  NC0341860  
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Fig. 1: Hepatocyte basolateral BA transporters. Protein-bound BAs returning in portal blood 
are taken up by the hepatocyte via the sodium taurocholate co-transporting poly-
peptide (NTCP) and organic-anion-transporting polypeptide (OATP). In cholestasis BAs 
may be returned to blood by the multi-drug-resistance-associated protein 3 (MRP3). 
BAs cross the hepatocyte bound to 3a-hydroxysteroid dehydrogenase (adapted from 
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Fig. 2: Secretion of BAs and biliary components. BAs are exported into the canaliculus by 
the bile-salt export protein (BSEP). Phosphatidylcholine (PC) from the inner leaflet of 
the apical membrane is flipped to the outer layer and interacts with BAs secreted by 
BSEP. BAs, PC, together with cholesterol from the membrane form mixed micelles that 
are not toxic to epithelial membranes of the biliary tree. Aquaporins (AQP) secrete 
water into bile (adapted from Jenkins et al., 2008). ........................................................ 11 
Fig. 3: BA absorption by the cholangiocyte in the cholehepatic shunt. BAs are absorbed at 
the apical membrane of the cholangiocyte by the apical sodium-dependent BA 
transporter (ASBT) that causes cholehepatic shunting of BAs back to the hepatocyte. 
Absorbed BAs are exported across the basolateral membrane by multi-drug-resistance-
associated protein 3 (MRP3), a truncated form of ASBT or by OSTα/OSTβ. BAs cause 
choleresis that is rich in bicarbonate ions secreted by the chloride/bicarbonate ion 
exchanger (adapted from Jenkins et al., 2008). ............................................................... 13 
Fig. 4: BA absorption from the small bowel lumen. BAs are efficiently transported from the 
lumen of the terminal ileum by the apical sodium-dependent BA transporter (ASBT). 
Unconjugated BAs will be un-ionised at the pH of the lumen and may be passively 
absorbed. Within the enterocyte BAs are bound by the intestinal BA-binding protein 
(IBABP). Efflux from the enterocyte may involve the truncated ASBT (tASBT) and/or 
multi-drug-resistance-associated protein 3 (MRP3) but this remains to be defined. 
OSTα/OSTβ gene products together but not separately transport BAs out of the 
enterocyte. OATP3 mRNA has been identified but it is not yet clear whether the protein 
is functional (adapted from Jenkins et al., 2008). ............................................................ 13 
Fig. 5: Impact on energy metabolism after FXR activation, e.g. by BAs or GW4064. 
Administration of the synthetic FXR agonist GW4064 to high-fat diet fed mice leads to a 
reduction in BA synthesis and reduced BA pool size. This translates into reduced energy 
expenditure in BAT, TG accumulation in WAT, BAT, and liver, as well as insulin 
resistance. As BAs are natural ligands for FXR and activate equal signal transduction 
routes, similar effects can be observed (adapted from Watanabe et al., 2011). ............ 15 
Fig. 6: Schematic illustration of bile acid-derived induction of thermogenesis. During 
digestion, bile acids are secreted with bile from the gallbladder and released into the 
intestine to emulsify dietary lipids, etc. They can be transferred back to the hepatocytes 
by intestinal reabsorption. Besides this recycling mechanism, which is called 
“enterohepatic circulation”, BAs also spillover from liver into plasma. Thereby they 
reach peripheral sites of action, amongst others brown adipose tissue, where they are 
supposed to bind to the G-protein-coupled BA receptor TGR5, thereby increase Ucp1 
expression and induce thermogenesis. ............................................................................ 20 
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Fig. 7: The effect of BAs on energy expenditure. Circulated BAs bind to the G-protein-
coupled BA receptor TGR5, which stimulates increased cAMP-PKA activation and 
increased expression of D2. This response is sensitized by a high-fat diet. D2 converts T4 
to active T3, which stimulates thyroid hormone receptor binding to target genes. This 
leads to an altered expression of genes associated with energy balance and increased 
energy expenditure (adapted from Jenkins and Hardie, 2008). ...................................... 21 
Fig. 8: Composition of experimental diets used in this thesis. The custom-made semi-
purified diets were obtained from Ssniff Spezialdiäten GmbH, Soest, Germany: (A) C, 
S5745-E702, (B) CC, S5745–E706, (C) H, S5745-E712, (D) HC, S5745–E716. 
Macronutrients are given in percent by weight. Weight of supplemented sodium 
cholate was equalized by the percentage weight reduction of corn starch. ................... 24 
Fig. 9: Overview of experimental setup for indirect calorimetry and subsequent feeding-
drinking-activity measurements (C: control diet, FDA: Feeding-drinking-activity 
measurement, H: high-fat diet, HC: high-fat diet supplemented with 0.5 % cholic acid, 
IVC: Individually ventilated cage). .................................................................................... 32 
Fig. 10: Cholic acid supplementation prevents diet-induced obesity in C57BL/6J mice due to 
fat mass reduction (n=4-7). Figure modified from Fromme et al. (2019). a) Cumulative 
food intake during 28 experimental days. Note: Food intake of only four H-fed animals 
was analysed due to exclusion of three food spilling animals). b) Mean energy intake at 
experimental day 28. Differences between supplemented and non-supplemented 
groups were t-tested. a) and b) Mean values with standard deviation are shown (n=4-7). 
c) Body mass development over 28 experimental days. CA-supplementation effectively 
prevented body mass gain of H-fed BL6J mice (BA main effect p=0.0024; Linear Mixed 
Effects Model), whereas supplementing CA to C diet does not affect body mass 
development (p=0.718). Mean values with standard error bars are shown (n=6-7). d) 
Total fat mass at experimental day 28. CA-supplementation impeded fat mass 
accumulation due to H feeding (p=0.0024). e) Total lean mass at experimental day 28. 
d) and e) Mean values with standard deviation are shown (n=6-7). ............................... 39 
Fig. 11: Assimilated energy and assimilation coefficient in BL6J mice after 28 experimental 
days (n=4-7). Mean values are shown, data points represent individual animals. ......... 40 
Fig. 12: Effects of CA-supplementation on BL6J iBAT mass, morphology and Ucp1 mRNA 
expression (n=6-7). Figure modified from Fromme et al. (2019). a) Mean BL6J iBAT 
mass: Comparison of interscapular brown adipose tissue (iBAT) masses according to 
different diets. Mean values with standard deviation are shown. b) Microscopic 
specimen of exemplary H&E-stained iBAT tissue slides. Scale bar: 50 µm. c) Relative 
BL6J Ucp1 mRNA expression in iBAT after 28 days of experimental diet feeding with or 
without cholic acid supplementation. Ucp1 gene expression measured by quantitative 
PCR. Transcript levels were normalized to the mean expression of Hsp90 and ActB. 
Means are shown, data points represent individual animals. Statistical significance 
between non-supplemented and CA-supplemented diet groups was tested using 
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Fig. 13: Effects of CA-supplementation on BL6J iWAT mass, morphology, brown adipocyte 
marker mRNA expression and occurrence of UCP1-positive cells (n=5-7). Figure 
modified from Fromme et al. (2019). a) Mean BL6J iWAT masses: Comparison of 
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inguinal white adipose tissue masses according to different diets. Mean values with 
standard deviation are shown (n=5-7). Statistical significance between non-
supplemented and CA-supplemented diet groups was tested using Student’s t-test. b) 
Microscopic specimen of exemplary H&E-stained iWAT tissue slides. Scale bar: 50 µm. 
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Fig. 16: Fat mass and lean mass before and after indirect calorimetry measurements (at 
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